Small Cell Lung Cancer

MONDO:0008433 Pathograph 8 Show in embeddings browser lung neoplasm

Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine lung malignancy characterized by rapid growth, early metastasis, and initial chemosensitivity followed by near-universal relapse. SCLC accounts for approximately 13-15% of lung cancers and is strongly associated with tobacco smoking. Molecularly, SCLC is defined by near-universal inactivation of both TP53 and RB1 tumor suppressors, leading to loss of cell cycle checkpoints and genomic instability. Unlike NSCLC, SCLC lacks actionable driver mutations and is treated primarily with chemotherapy plus immunotherapy. Despite high initial response rates, long-term survival remains poor.

Ask OpenScientist

Ask a research question about Small Cell Lung Cancer. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

10
Pathophys.
1
Histopath.
4
Phenotypes
8
Pathograph
4
Genes
9
Medical Actions
6
Subtypes
5
Datasets
1
Deep Research
🏷

Classifications

ICD-O Morphology
Carcinoma
Harrison's Part
ONCOLOGY HEMATOLOGY
◆

Subtypes

6
Limited-Stage SCLC
Disease confined to one hemithorax that can be encompassed within a tolerable radiation field. Approximately 30% of SCLC presents as limited-stage. Treatment includes concurrent chemoradiation with potential for cure.
Extensive-Stage SCLC
Disease beyond a single hemithorax or with distant metastases. Approximately 70% of SCLC presents as extensive-stage. Treated with chemotherapy plus immunotherapy; not curable but can achieve meaningful responses.
SCLC-A (ASCL1-high)
SCLC subtype defined by high ASCL1 expression. Associated with classic neuroendocrine phenotype and may respond differently to therapy.
SCLC-N (NEUROD1-high)
SCLC subtype defined by high NEUROD1 expression. Variant neuroendocrine phenotype.
SCLC-P (POU2F3-high)
SCLC subtype defined by high POU2F3 expression. Tuft cell-like phenotype, may lack classic neuroendocrine markers.
SCLC-Y (YAP1-high)
SCLC subtype with YAP1 activation. Non-neuroendocrine phenotype, may arise from epithelial-mesenchymal transition.
⚙

Pathophysiology

10
TP53 Inactivation
TP53 is inactivated in >90% of SCLC through mutations, deletions, or both. Loss of p53 function eliminates the G1/S checkpoint and apoptotic response to DNA damage, enabling survival despite genomic instability.
type II pneumocyte CL:0002063 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves type II pneumocyte, annotated with pulmonary alveolar type 2 cell (CL:0002063). CL:0002063 is a cell type from the Cell Ontology.
DNA damage response, signal transduction by p53 class mediator GO:0030330 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves absent DNA damage response, signal transduction by p53 class mediator (GO:0030330). GO:0030330 is a biological process from the Gene Ontology. ∅ ABSENT
Downstream
Loss of Cell Cycle Checkpoints Cells proliferate despite DNA damage
Show evidence (1 reference)
PMID:36399634 SUPPORT
"The canonical model of "small cell lung cancer" (SCLC) depicts tumors arising from dual inactivation of TP53 and RB1."
Abstract states the canonical model involves TP53 and RB1 inactivation.
RB1 Inactivation
RB1 is inactivated in >90% of SCLC through mutations, deletions, or both. Loss of Rb function eliminates the G1/S checkpoint by releasing E2F transcription factors, enabling uncontrolled S-phase entry.
negative regulation of G1/S transition of mitotic cell cycle GO:2000134 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves absent negative regulation of G1/S transition of mitotic cell cycle (GO:2000134). GO:2000134 is a biological process from the Gene Ontology. ∅ ABSENT
Downstream
Loss of Cell Cycle Checkpoints Uncontrolled cell cycle progression
Show evidence (1 reference)
PMID:36399634 SUPPORT
"The canonical model of "small cell lung cancer" (SCLC) depicts tumors arising from dual inactivation of TP53 and RB1."
Abstract states the canonical model involves TP53 and RB1 inactivation.
Loss of Cell Cycle Checkpoints
Combined TP53 and RB1 loss eliminates major cell cycle checkpoints. Cells proliferate rapidly without the normal restraints on replication. This explains the rapid doubling time and initial chemosensitivity (dividing cells are vulnerable to chemotherapy).
cell population proliferation GO:0008283 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased cell population proliferation (GO:0008283). GO:0008283 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Genomic Instability Accumulation of mutations and chromosomal alterations
Show evidence (1 reference)
PMID:38473726 SUPPORT Other
"their broad tumor suppressive functions are eliminated and a normal cell is able to proliferate indefinitely, escape entering into cellular senescence, and evade death"
Mechanistic review of p53/RB aberrations in SCLC states that combined TP53/RB1 loss removes tumor-suppressive checkpoints, allowing indefinite proliferation and senescence/death escape.
Genomic Instability
Loss of TP53 and RB1 leads to widespread genomic instability with frequent chromosomal gains and losses. Amplification of MYC family genes (MYC, MYCL, MYCN) occurs in ~20% of SCLC and is associated with worse prognosis.
DNA repair GO:0006281 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal DNA repair (GO:0006281). GO:0006281 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Show evidence (1 reference)
PMID:37329269 SUPPORT Other
"Genomic profiling of SCLC reveals genetic instability"
Comprehensive clinical review reports that genomic profiling of SCLC tumors demonstrates genetic instability (alongside near-universal TP53/RB1 loss and high mutation burden).
Neuroendocrine Differentiation
SCLC cells exhibit neuroendocrine differentiation, expressing markers such as synaptophysin, chromogranin A, and CD56 (NCAM). Neuroendocrine phenotype is regulated by lineage transcription factors (ASCL1, NEUROD1). Some SCLC produces paraneoplastic hormones (ACTH, ADH).
neuron differentiation GO:0030182 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal neuron differentiation (GO:0030182). GO:0030182 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Functional Neuron-SCLC Synapses The neuroendocrine/neuronal-like differentiation program enables SCLC cells to form functional synapses with neurons.
Lineage Transcription Factor Subtypes and State Plasticity
SCLC is a transcriptionally heterogeneous disease that is subclassified by lineage-defining transcription factors (ASCL1/SCLC-A, NEUROD1/SCLC-N, POU2F3/SCLC-P, YAP1/SCLC-Y) plus an inflamed subtype (SCLC-I). Subtype identity is largely epigenetically rather than mutationally determined: the SWI/SNF ATPase SMARCA4 binds ASCL1 and NEUROD1 loci to maintain the neuroendocrine program, and tumors show plasticity toward low-neuroendocrine states during progression or acquired chemoresistance.
chromatin remodeling GO:0006338 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal chromatin remodeling (GO:0006338). GO:0006338 is a biological process from the Gene Ontology. ⚠ ABNORMAL neuron differentiation GO:0030182 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal neuron differentiation (GO:0030182). GO:0030182 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Show evidence (2 references)
PMID:40333678 SUPPORT Other
"distinct molecular subtypes driven by lineage-defining transcription factors, including ASCL1, NEUROD1, POU2F3, and YAP1, as well as an inflamed subtype (SCLC-I)"
Multi-omic review establishes the transcription-factor-defined molecular subtypes of SCLC (ASCL1, NEUROD1, POU2F3, YAP1, and inflamed SCLC-I).
PMID:39080761 SUPPORT In Vitro
"SMARCA4 binds to gene loci encoding NE-lineage transcription factors ASCL1 and NEUROD1 and alters chromatin accessibility, enhancing NE programs"
ChIPseq/ATACseq study in SCLC cell lines and PDXs shows SMARCA4 regulates chromatin accessibility at ASCL1/NEUROD1 loci, controlling neuroendocrine-state plasticity.
Immune Evasion
SCLC employs multiple immune-evasive mechanisms that blunt the benefit of PD-1/PD-L1 checkpoint blockade, including T-cell exclusion (the "immune desert" phenotype of neuroendocrine-high tumors), downregulation of the MHC class I antigen processing and presentation machinery, and upregulation of macrophage inhibitory checkpoints.
antigen processing and presentation via MHC class I GO:0002474 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased antigen processing and presentation via MHC class I, annotated with antigen processing and presentation of peptide antigen via MHC class I (GO:0002474). GO:0002474 is a biological process from the Gene Ontology. ↓ DECREASED negative regulation of T cell mediated immunity GO:0002710 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased negative regulation of T cell mediated immunity (GO:0002710). GO:0002710 is a biological process from the Gene Ontology. ↑ INCREASED
Show evidence (1 reference)
PMID:38630789 SUPPORT Other
"Several immune evasive mechanisms have been shown to be prominently altered in human SCLC, including T-cell exclusion, downregulation of components of the MHC class I antigen processing and presentation machinery"
Review of human SCLC immunobiology documents T-cell exclusion, MHC class I downregulation, and macrophage checkpoint upregulation as dominant immune-evasion mechanisms.
Functional Neuron-SCLC Synapses
SCLC cells can form functional synapses with neurons and receive synaptic transmission.
synapse assembly GO:0007416 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal synapse assembly (GO:0007416). GO:0007416 is a biological process from the Gene Ontology. ⚠ ABNORMAL chemical synaptic transmission GO:0007268 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal chemical synaptic transmission (GO:0007268). GO:0007268 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Neuron-Driven Proliferation Synaptic input from neurons drives the pro-proliferative response of SCLC cells.
Glutamate Signaling Dependency Neuronal synaptic transmission engages glutamatergic signaling that the tumor becomes dependent on.
Show evidence (1 reference)
PMID:40931078 SUPPORT In Vitro
"Here we show that SCLC cells can form functional synapses and receive synaptic transmission."
In vitro neuron-SCLC co-culture reports functional synapses and synaptic transmission between neurons and SCLC cells.
Neuron-Driven Proliferation
SCLC cells gain a proliferation advantage when co-cultured with neurons.
positive regulation of cell population proliferation GO:0008284 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased positive regulation of cell population proliferation (GO:0008284). GO:0008284 is a biological process from the Gene Ontology. ↑ INCREASED
Show evidence (1 reference)
PMID:40931078 SUPPORT In Vitro
"we showed that SCLC cells derive a proliferation advantage when co-cultured with vagal sensory or cortical neurons."
In vitro co-culture with vagal sensory or cortical neurons provides a proliferation advantage to SCLC cells.
Glutamate Signaling Dependency
Inhibition of glutamate signaling has therapeutic efficacy in SCLC models, implicating glutamatergic signaling in tumor growth.
glutamate receptor signaling pathway GO:0007215 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal glutamate receptor signaling pathway (GO:0007215). GO:0007215 is a biological process from the Gene Ontology. ⚠ ABNORMAL synaptic transmission, glutamatergic GO:0035249 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal synaptic transmission, glutamatergic (GO:0035249). GO:0035249 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Show evidence (1 reference)
PMID:40931078 SUPPORT Model Organism
"Moreover, inhibition of glutamate signalling had therapeutic efficacy in an autochthonous mouse model of SCLC."
Glutamate-signaling inhibition shows therapeutic efficacy in an autochthonous SCLC mouse model, implicating glutamatergic dependency in tumor growth.
✶

Histopathology

1
Neuroendocrine Carcinoma VERY_FREQUENT
Small-cell lung cancer is a very aggressive neuroendocrine carcinoma.
Show evidence (1 reference)
PMID:24734358 SUPPORT
"Small-cell lung cancer (SCLC) is a very aggressive neuroendocrine carcinoma"
Abstract defines SCLC as a very aggressive neuroendocrine carcinoma.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Small Cell Lung Cancer Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

4
Lung Neoplasm OBLIGATE Neoplastic HP:0100526 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Neoplasm of the lung (HP:0100526). HP:0100526 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:33446664 SUPPORT Human Clinical
"Distinct clinical characteristics of SCLC include the predominantly central location of the primary tumour in the major airways and the often extensive extrapulmonary metastatic spread at presentation."
Supports SCLC presenting as a centrally located primary lung mass with extensive intrathoracic/mediastinal spread; peripheral nodules are rare.
Smoking Association VERY_FREQUENT Clinical HP:0100526 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Neoplasm of the lung (HP:0100526). HP:0100526 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:33446664 SUPPORT Human Clinical
"SCLC is strongly associated with smoking, with 98% of cases arising in current or former smokers"
Supports the dominant tobacco-smoking risk-factor association for SCLC, with the vast majority of cases occurring in current or former smokers.
Brain Metastases VERY_FREQUENT Clinical HP:0004375 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Neoplasm of the nervous system (HP:0004375). HP:0004375 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:17699816 SUPPORT Human Clinical
"The cumulative risk of brain metastases within 1 year was 14.6% in the irradiation group (95% CI, 8.3 to 20.9) and 40.4% in the control group"
Randomized trial quantifies the high incidence of brain metastases in extensive SCLC and shows prophylactic cranial irradiation substantially reduces this risk in responders.
Paraneoplastic Syndromes OCCASIONAL Clinical HP:0100526 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Neoplasm of the lung (HP:0100526). HP:0100526 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:33209464 SUPPORT Human Clinical
"Paraneoplastic syndromes can commonly occur due to lung cancer, especially small cell lung cancer."
Review establishes SCLC as the classic cause of paraneoplastic syndromes (endocrine syndromes such as SIADH/ectopic ACTH and antibody-mediated neurologic syndromes such as Lambert-Eaton).
🧬

Genetic Associations

4
TP53 (Somatic Inactivating Mutation)
Gene: TP53 hgnc:11998 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is TP53 (hgnc:11998). hgnc:11998 is a gene from the HUGO Gene Nomenclature Committee.
Somatic
Show evidence (1 reference)
PMID:38473726 SUPPORT Other
"The genes coding for the tumor suppressors p53 and retinoblastoma (Rb) are inactivated in the vast majority of small cell lung cancer (SCLC) tumors."
Documents near-universal TP53 (p53) inactivation in SCLC.
RB1 (Somatic Inactivating Mutation)
Gene: RB1 hgnc:9884 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is RB1 (hgnc:9884). hgnc:9884 is a gene from the HUGO Gene Nomenclature Committee.
Somatic
Show evidence (1 reference)
PMID:38473726 SUPPORT Other
"Data support the notion that these two deleterious genetic events represent the initial steps in the development of SCLC"
Documents RB1 (Rb) loss, alongside TP53, as an initiating genetic event essentially universal in SCLC.
MYC (Amplification)
Gene: MYC hgnc:7553 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is MYC (hgnc:7553). hgnc:7553 is a gene from the HUGO Gene Nomenclature Committee.
Somatic
NOTCH (Somatic Inactivating Mutation)
Somatic
💊

Medical Actions

9
Platinum-Etoposide Chemotherapy
Action: chemotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is chemotherapy (NCIT:C15632). NCIT:C15632 is a clinical intervention from the NCI Thesaurus. Ontology label: Chemotherapy NCIT:C15632
Carboplatin or cisplatin plus etoposide is the backbone of SCLC treatment. High initial response rates (60-80%) but nearly universal relapse. Four cycles is standard for extensive-stage; concurrent with radiation for limited-stage.
Show evidence (1 reference)
PMID:40843764 SUPPORT Other
"For ES-SCLC, the treatment paradigm has been fundamentally transformed by the integration of immune checkpoint inhibitors (ICIs) with platinum-etoposide chemotherapy, establishing a new standard of care"
Integration of immune checkpoint inhibitors with platinum-etoposide chemotherapy is the standard-of-care backbone for extensive-stage SCLC.
Atezolizumab (with Chemotherapy)
Action: immunotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is immunotherapy (NCIT:C15262). NCIT:C15262 is a clinical intervention from the NCI Thesaurus. Ontology label: Immunotherapy NCIT:C15262
Agent: atezolizumab NCIT:C106250 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses atezolizumab (NCIT:C106250). NCIT:C106250 is a therapeutic agent from the NCI Thesaurus.
PD-L1 checkpoint inhibitor added to carboplatin-etoposide for extensive-stage SCLC. IMpower133 trial showed modest overall survival benefit. Now standard first-line for extensive-stage.
Durvalumab (with Chemotherapy)
Action: immunotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is immunotherapy (NCIT:C15262). NCIT:C15262 is a clinical intervention from the NCI Thesaurus. Ontology label: Immunotherapy NCIT:C15262
Agent: durvalumab NCIT:C103194 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses durvalumab (NCIT:C103194). NCIT:C103194 is a therapeutic agent from the NCI Thesaurus.
PD-L1 checkpoint inhibitor added to platinum-etoposide for extensive-stage SCLC. CASPIAN trial showed overall survival benefit. Alternative to atezolizumab-based regimen.
Thoracic Radiation
Action: radiation therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is radiation therapy (NCIT:C15313). NCIT:C15313 is a clinical intervention from the NCI Thesaurus. Ontology label: Radiation Therapy NCIT:C15313
Concurrent thoracic radiation with chemotherapy for limited-stage SCLC. Essential component of potentially curative therapy. Consolidative thoracic radiation may also benefit select extensive-stage patients.
Prophylactic Cranial Irradiation
Action: radiation therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is radiation therapy (NCIT:C15313). NCIT:C15313 is a clinical intervention from the NCI Thesaurus. Ontology label: Radiation Therapy NCIT:C15313
Whole-brain radiation to prevent brain metastases in responding patients. Reduces brain metastasis incidence but controversial due to neurocognitive effects. Alternative is surveillance with MRI.
Lurbinectedin
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: lurbinectedin CHEBI:746908 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses lurbinectedin (CHEBI:746908). CHEBI:746908 is a therapeutic agent from Chemical Entities of Biological Interest.
Transcription inhibitor approved for relapsed SCLC. Alternative to topotecan for second-line treatment. Works by inhibiting oncogenic transcription factors.
Topotecan
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: topotecan CHEBI:63632 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses topotecan (CHEBI:63632). CHEBI:63632 is a therapeutic agent from Chemical Entities of Biological Interest.
Topoisomerase I inhibitor used for relapsed SCLC. Standard second-line option, though responses are generally modest and short-lived.
Tarlatamab
Action: immunotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is immunotherapy (NCIT:C15262). NCIT:C15262 is a clinical intervention from the NCI Thesaurus. Ontology label: Immunotherapy NCIT:C15262
Agent: tarlatamab NCIT:C175858 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses tarlatamab (NCIT:C175858). NCIT:C175858 is a therapeutic agent from the NCI Thesaurus.
DLL3-directed bispecific T-cell engager (DLL3 x CD3 BiTE) that redirects T cells against the neuroendocrine-lineage surface antigen DLL3, which is highly expressed in SCLC. FDA-approved in 2024 for relapsed/refractory extensive-stage SCLC. Represents the most clinically advanced DLL3-targeted immunotherapy.
Show evidence (2 references)
PMID:38630789 SUPPORT Other
"delta-like ligand 3-targeted bispecific T-cell engagers have shown the most compelling preliminary evidence of clinical efficacy"
Immunotherapy review highlights DLL3-targeted bispecific T-cell engagers (tarlatamab) as the most clinically promising emerging immunotherapy for SCLC.
PMID:37627044 SUPPORT Other
"The potential of targeting DLL3, a NOTCH ligand, through antibody-drug conjugates, bispecific T-cell engagers, and CAR T-cell therapy"
Precision-therapy review identifies DLL3 as a key SCLC surface target for bispecific T-cell engagers, ADCs, and CAR-T approaches.
Benmelstobart plus Anlotinib with Chemotherapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: benmelstobart NCIT:C156692 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses benmelstobart (NCIT:C156692). NCIT:C156692 is a therapeutic agent from the NCI Thesaurus. anlotinib NCIT:C138997 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses anlotinib, annotated with Catequentinib (NCIT:C138997). NCIT:C138997 is a therapeutic agent from the NCI Thesaurus.
First-line extensive-stage SCLC regimen adding the PD-L1 inhibitor benmelstobart and the multi-target anti-angiogenic small molecule anlotinib to etoposide/carboplatin (ETER701 trial). This immunochemotherapy plus anti-angiogenesis combination achieved a median overall survival of 19.3 months, greater than in prior randomized ES-SCLC studies.
Show evidence (1 reference)
PMID:38992123 SUPPORT Human Clinical
"median OS was prolonged with benmelstobart and anlotinib plus EC"
Randomized phase 3 ETER701 trial shows adding benmelstobart (PD-L1 inhibitor) plus anlotinib (anti-angiogenic) to etoposide/carboplatin prolongs overall survival in extensive-stage SCLC.
🌍

Environmental Factors

1
Tobacco Smoking
exposure to tobacco smoking ECTO:6000029 Environmental Conditions, Treatments and Exposures Ontology (ECTO) Relation: this environmental factor is this exposure This environmental factor is exposure to tobacco smoking (ECTO:6000029). ECTO:6000029 is an exposure from the Environmental Conditions, Treatments and Exposures Ontology.
Cigarette smoking is the dominant risk factor for SCLC, with a much stronger association than for lung adenocarcinoma. Tobacco carcinogens drive widespread genomic damage and contribute to TP53 and RB1 inactivation.
Show evidence (1 reference)
PMID:8166467 SUPPORT
"Cigarette smoking and occupational risk factors are more strongly associated with squamous and small cell lung cancers than with adenocarcinoma."
Supports the strong association between SCLC and cigarette smoking.
🔬

Biochemical Markers

1
Neuroendocrine Markers
Show evidence (1 reference)
PMID:33687006 SUPPORT
"markers which included synaptophysin, chromogranin, CD56"
Pulmonary neuroendocrine tumor study notes diagnostic IHC panel includes classic neuroendocrine markers used for SCLC.
📊

Prevalence

1
United States
Annual Incidence 4.6 per 100,000 1–9 per 100,000
SEER age-adjusted incidence rate, 2020 (declined from 9 per 100,000 in 2000, ~3% average annual decrease, paralleling reduced smoking rates).
Show evidence (1 reference)
PMID:39908169 SUPPORT Human Clinical
"from 9 per 100,000 in 2000 to 4.6 per 100,000 in 2020"
SEER analysis of 188,426 US SCLC patients reports the age-adjusted incidence declined to 4.6 per 100,000 in 2020.
📊

Related Datasets

5
A small cell lung cancer genome reports complex tobacco exposure signatures ega:EGAS00000000051
Cancer is driven by mutation. Worldwide, tobacco smoking is the major lifestyle exposure that causes cancer, exerting carcinogenicity through 60 chemicals that bind and mutate DNA. Using massively parallel sequencing technology, we sequenced a small cell lung cancer cell line, NCI-H209, to explore the mutational burden associated with tobacco smoking. 22,910 somatic substitutions were identified, including 132 in coding exons. Multiple mutation signatures testify to the cocktail of carcinogens in tobacco smoke and their proclivities for particular bases and surrounding sequence context.
human WGS
European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Small Cell Lung Cancer"); description-level mentions were not accepted. EGA study_type: Whole Genome Sequencing. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.
Integrative analysis of small cell lung cancer ega:EGAS00001000299
Small-cell lung cancer (SCLC) is an aggressive lung tumor subtype. We conducted integrated analysis of genome sequencing, transcriptome, and copy number analysis and found an extremely high mutation rate of 7.4±1 protein-changing mutations per million basepairs. Evidence for inactivation of TP53 and RB1 was found in all sequenced cases. Furthermore, we identified recurrent mutations in CREBBP, EP300, and MLL, observed mutations in PTEN, in SLIT2, and EPHA7, as well as focal amplifications of the FGFR1 locus.
human
PMID:22941188
European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Small Cell Lung Cancer"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.
Genentech Small Cell Lung Cancer (SCLC) Screen ega:EGAS00001000334
Exome capture, RNA-Seq, whole genome sequencing of set of Small Cell Lung Cancer samples.
human
PMID:22941189
European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Small Cell Lung Cancer"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.
Small cell lung cancer metabolome (part II) metabolomics_workbench:ST000220
Located via OmicsDI, which aggregates across omics repositories; this record comes from metabolomics_workbench. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Small Cell Lung Cancer"). Retrieved 2026-08-02.
The NFIB/CARM1 Partnership is a Therapeutic Target for Small Cell Lung Cancer massive:MSV000090746
This project identified NFI family members as CARM1 substrates. NFIB was previously reported to play a critical role in the development of small cell lung cancer. We provided evidence that the arginine methylation of NFIB is required for its oncogenic function in small cell lung cancer.
Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Small Cell Lung Cancer"). Retrieved 2026-08-02.
{ }

Source YAML

click to show 
name: Small Cell Lung Cancer
creation_date: '2026-01-26T02:55:13Z'
description: >-
  Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine lung malignancy
  characterized by rapid growth, early metastasis, and initial chemosensitivity followed
  by near-universal relapse. SCLC accounts for approximately 13-15% of lung cancers and
  is strongly associated with tobacco smoking. Molecularly, SCLC is defined by near-universal
  inactivation of both TP53 and RB1 tumor suppressors, leading to loss of cell cycle
  checkpoints and genomic instability. Unlike NSCLC, SCLC lacks actionable driver mutations
  and is treated primarily with chemotherapy plus immunotherapy. Despite high initial
  response rates, long-term survival remains poor.
categories:
- Neuroendocrine Neoplasm
- Lung Cancer Subtype
- Solid Tumor
parents:
- lung neoplasm
has_subtypes:
- name: Limited-Stage SCLC
  description: >-
    Disease confined to one hemithorax that can be encompassed within a tolerable
    radiation field. Approximately 30% of SCLC presents as limited-stage. Treatment
    includes concurrent chemoradiation with potential for cure.
- name: Extensive-Stage SCLC
  description: >-
    Disease beyond a single hemithorax or with distant metastases. Approximately
    70% of SCLC presents as extensive-stage. Treated with chemotherapy plus
    immunotherapy; not curable but can achieve meaningful responses.
- name: SCLC-A (ASCL1-high)
  description: >-
    SCLC subtype defined by high ASCL1 expression. Associated with classic
    neuroendocrine phenotype and may respond differently to therapy.
- name: SCLC-N (NEUROD1-high)
  description: >-
    SCLC subtype defined by high NEUROD1 expression. Variant neuroendocrine
    phenotype.
- name: SCLC-P (POU2F3-high)
  description: >-
    SCLC subtype defined by high POU2F3 expression. Tuft cell-like phenotype,
    may lack classic neuroendocrine markers.
- name: SCLC-Y (YAP1-high)
  description: >-
    SCLC subtype with YAP1 activation. Non-neuroendocrine phenotype, may arise
    from epithelial-mesenchymal transition.
environmental:
- name: Tobacco Smoking
  description: >-
    Cigarette smoking is the dominant risk factor for SCLC, with a much stronger
    association than for lung adenocarcinoma. Tobacco carcinogens drive widespread
    genomic damage and contribute to TP53 and RB1 inactivation.
  evidence:
  - reference: PMID:8166467
    reference_title: "Overview on small cell lung cancer in the world: industrialized countries, Third World, eastern Europe."
    supports: SUPPORT
    snippet: "Cigarette smoking and occupational risk factors are more strongly associated with squamous and small cell lung cancers than with adenocarcinoma."
    explanation: "Supports the strong association between SCLC and cigarette smoking."
  exposure_term:
    preferred_term: exposure to tobacco smoking
    term:
      id: ECTO:6000029
      label: exposure to tobacco smoking
pathophysiology:
- name: TP53 Inactivation
  description: >-
    TP53 is inactivated in >90% of SCLC through mutations, deletions, or both.
    Loss of p53 function eliminates the G1/S checkpoint and apoptotic response
    to DNA damage, enabling survival despite genomic instability.
  evidence:
  - reference: PMID:36399634
    reference_title: "Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer."
    supports: SUPPORT
    snippet: 'The canonical model of "small cell lung cancer" (SCLC) depicts tumors arising from dual inactivation of TP53 and RB1.'
    explanation: "Abstract states the canonical model involves TP53 and RB1 inactivation."
  cell_types:
  - preferred_term: type II pneumocyte
    term:
      id: CL:0002063
      label: pulmonary alveolar type 2 cell
  biological_processes:
  - preferred_term: DNA damage response, signal transduction by p53 class mediator
    modifier: ABSENT
    term:
      id: GO:0030330
      label: DNA damage response, signal transduction by p53 class mediator
  downstream:
  - target: Loss of Cell Cycle Checkpoints
    description: Cells proliferate despite DNA damage
- name: RB1 Inactivation
  description: >-
    RB1 is inactivated in >90% of SCLC through mutations, deletions, or both.
    Loss of Rb function eliminates the G1/S checkpoint by releasing E2F
    transcription factors, enabling uncontrolled S-phase entry.
  evidence:
  - reference: PMID:36399634
    reference_title: "Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer."
    supports: SUPPORT
    snippet: 'The canonical model of "small cell lung cancer" (SCLC) depicts tumors arising from dual inactivation of TP53 and RB1.'
    explanation: "Abstract states the canonical model involves TP53 and RB1 inactivation."
  biological_processes:
  - preferred_term: negative regulation of G1/S transition of mitotic cell cycle
    modifier: ABSENT
    term:
      id: GO:2000134
      label: negative regulation of G1/S transition of mitotic cell cycle
  downstream:
  - target: Loss of Cell Cycle Checkpoints
    description: Uncontrolled cell cycle progression
- name: Loss of Cell Cycle Checkpoints
  conforms_to: "evading_growth_suppressors#Loss of Cell-Cycle Checkpoint Control"
  description: >-
    Combined TP53 and RB1 loss eliminates major cell cycle checkpoints. Cells
    proliferate rapidly without the normal restraints on replication. This
    explains the rapid doubling time and initial chemosensitivity (dividing
    cells are vulnerable to chemotherapy).
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  evidence:
  - reference: PMID:38473726
    reference_title: "P53 and Rb Aberrations in Small Cell Lung Cancer (SCLC): From Molecular Mechanisms to Therapeutic Modulation."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "their broad tumor suppressive functions are eliminated and a normal cell is able to proliferate indefinitely, escape entering into cellular senescence, and evade death"
    explanation: "Mechanistic review of p53/RB aberrations in SCLC states that combined TP53/RB1 loss removes tumor-suppressive checkpoints, allowing indefinite proliferation and senescence/death escape."
  downstream:
  - target: Genomic Instability
    description: Accumulation of mutations and chromosomal alterations
- name: Genomic Instability
  conforms_to: "genome_instability_mutation#Mutator Phenotype and Chromosomal Instability"
  description: >-
    Loss of TP53 and RB1 leads to widespread genomic instability with frequent
    chromosomal gains and losses. Amplification of MYC family genes (MYC, MYCL,
    MYCN) occurs in ~20% of SCLC and is associated with worse prognosis.
  biological_processes:
  - preferred_term: DNA repair
    modifier: ABNORMAL
    term:
      id: GO:0006281
      label: DNA repair
  evidence:
  - reference: PMID:37329269
    reference_title: "Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Genomic profiling of SCLC reveals genetic instability"
    explanation: "Comprehensive clinical review reports that genomic profiling of SCLC tumors demonstrates genetic instability (alongside near-universal TP53/RB1 loss and high mutation burden)."
- name: Neuroendocrine Differentiation
  description: >-
    SCLC cells exhibit neuroendocrine differentiation, expressing markers such
    as synaptophysin, chromogranin A, and CD56 (NCAM). Neuroendocrine phenotype
    is regulated by lineage transcription factors (ASCL1, NEUROD1). Some SCLC
    produces paraneoplastic hormones (ACTH, ADH).
  biological_processes:
  - preferred_term: neuron differentiation
    modifier: ABNORMAL
    term:
      id: GO:0030182
      label: neuron differentiation
  downstream:
  - target: Functional Neuron-SCLC Synapses
    description: >-
      The neuroendocrine/neuronal-like differentiation program enables SCLC
      cells to form functional synapses with neurons.
- name: Lineage Transcription Factor Subtypes and State Plasticity
  description: >-
    SCLC is a transcriptionally heterogeneous disease that is subclassified by
    lineage-defining transcription factors (ASCL1/SCLC-A, NEUROD1/SCLC-N,
    POU2F3/SCLC-P, YAP1/SCLC-Y) plus an inflamed subtype (SCLC-I). Subtype
    identity is largely epigenetically rather than mutationally determined:
    the SWI/SNF ATPase SMARCA4 binds ASCL1 and NEUROD1 loci to maintain the
    neuroendocrine program, and tumors show plasticity toward low-neuroendocrine
    states during progression or acquired chemoresistance.
  biological_processes:
  - preferred_term: chromatin remodeling
    modifier: ABNORMAL
    term:
      id: GO:0006338
      label: chromatin remodeling
  - preferred_term: neuron differentiation
    modifier: ABNORMAL
    term:
      id: GO:0030182
      label: neuron differentiation
  evidence:
  - reference: PMID:40333678
    reference_title: "Molecular Subtypes and Targeted Therapeutic Strategies in Small Cell Lung Cancer: Advances, Challenges, and Future Perspectives."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "distinct molecular subtypes driven by lineage-defining transcription factors, including ASCL1, NEUROD1, POU2F3, and YAP1, as well as an inflamed subtype (SCLC-I)"
    explanation: "Multi-omic review establishes the transcription-factor-defined molecular subtypes of SCLC (ASCL1, NEUROD1, POU2F3, YAP1, and inflamed SCLC-I)."
  - reference: PMID:39080761
    reference_title: "SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "SMARCA4 binds to gene loci encoding NE-lineage transcription factors ASCL1 and NEUROD1 and alters chromatin accessibility, enhancing NE programs"
    explanation: "ChIPseq/ATACseq study in SCLC cell lines and PDXs shows SMARCA4 regulates chromatin accessibility at ASCL1/NEUROD1 loci, controlling neuroendocrine-state plasticity."
- name: Immune Evasion
  conforms_to: "immune_checkpoint_blockade#Adaptive Immune Resistance"
  description: >-
    SCLC employs multiple immune-evasive mechanisms that blunt the benefit of
    PD-1/PD-L1 checkpoint blockade, including T-cell exclusion (the "immune
    desert" phenotype of neuroendocrine-high tumors), downregulation of the
    MHC class I antigen processing and presentation machinery, and upregulation
    of macrophage inhibitory checkpoints.
  biological_processes:
  - preferred_term: antigen processing and presentation via MHC class I
    modifier: DECREASED
    term:
      id: GO:0002474
      label: antigen processing and presentation of peptide antigen via MHC class I
  - preferred_term: negative regulation of T cell mediated immunity
    modifier: INCREASED
    term:
      id: GO:0002710
      label: negative regulation of T cell mediated immunity
  evidence:
  - reference: PMID:38630789
    reference_title: "Facts and Hopes on Cancer Immunotherapy for Small Cell Lung Cancer."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Several immune evasive mechanisms have been shown to be prominently altered in human SCLC, including T-cell exclusion, downregulation of components of the MHC class I antigen processing and presentation machinery"
    explanation: "Review of human SCLC immunobiology documents T-cell exclusion, MHC class I downregulation, and macrophage checkpoint upregulation as dominant immune-evasion mechanisms."
- name: Functional Neuron-SCLC Synapses
  description: >-
    SCLC cells can form functional synapses with neurons and receive synaptic
    transmission.
  biological_processes:
  - preferred_term: synapse assembly
    modifier: ABNORMAL
    term:
      id: GO:0007416
      label: synapse assembly
  - preferred_term: chemical synaptic transmission
    modifier: ABNORMAL
    term:
      id: GO:0007268
      label: chemical synaptic transmission
  evidence:
  - reference: PMID:40931078
    reference_title: "Functional synapses between neurons and small cell lung cancer."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Here we show that SCLC cells can form functional synapses and receive synaptic transmission."
    explanation: "In vitro neuron-SCLC co-culture reports functional synapses and synaptic transmission between neurons and SCLC cells."
  downstream:
  - target: Neuron-Driven Proliferation
    description: >-
      Synaptic input from neurons drives the pro-proliferative response of
      SCLC cells.
  - target: Glutamate Signaling Dependency
    description: >-
      Neuronal synaptic transmission engages glutamatergic signaling that the
      tumor becomes dependent on.
- name: Neuron-Driven Proliferation
  description: >-
    SCLC cells gain a proliferation advantage when co-cultured with neurons.
  biological_processes:
  - preferred_term: positive regulation of cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008284
      label: positive regulation of cell population proliferation
  evidence:
  - reference: PMID:40931078
    reference_title: "Functional synapses between neurons and small cell lung cancer."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "we showed that SCLC cells derive a proliferation advantage when co-cultured with vagal sensory or cortical neurons."
    explanation: "In vitro co-culture with vagal sensory or cortical neurons provides a proliferation advantage to SCLC cells."
  downstream: []
- name: Glutamate Signaling Dependency
  description: >-
    Inhibition of glutamate signaling has therapeutic efficacy in SCLC models,
    implicating glutamatergic signaling in tumor growth.
  biological_processes:
  - preferred_term: glutamate receptor signaling pathway
    modifier: ABNORMAL
    term:
      id: GO:0007215
      label: glutamate receptor signaling pathway
  - preferred_term: synaptic transmission, glutamatergic
    modifier: ABNORMAL
    term:
      id: GO:0035249
      label: synaptic transmission, glutamatergic
  evidence:
  - reference: PMID:40931078
    reference_title: "Functional synapses between neurons and small cell lung cancer."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Moreover, inhibition of glutamate signalling had therapeutic efficacy in an autochthonous mouse model of SCLC."
    explanation: "Glutamate-signaling inhibition shows therapeutic efficacy in an autochthonous SCLC mouse model, implicating glutamatergic dependency in tumor growth."
  downstream: []
histopathology:
- name: Neuroendocrine Carcinoma
  finding_term:
    preferred_term: Neuroendocrine Carcinoma
    term:
      id: NCIT:C3773
      label: Neuroendocrine Carcinoma
  frequency: VERY_FREQUENT
  description: Small-cell lung cancer is a very aggressive neuroendocrine carcinoma.
  evidence:
  - reference: PMID:24734358
    reference_title: "[Role of surgery in small cell lung cancer]."
    supports: SUPPORT
    snippet: "Small-cell lung cancer (SCLC) is a \nvery aggressive neuroendocrine carcinoma"
    explanation: Abstract defines SCLC as a very aggressive neuroendocrine carcinoma.

phenotypes:
- category: Neoplastic
  name: Lung Neoplasm
  frequency: OBLIGATE
  description: >-
    SCLC typically presents as a central/hilar mass with extensive mediastinal
    lymphadenopathy. Peripheral nodules are rare.
  phenotype_term:
    preferred_term: Neoplasm of the lung
    term:
      id: HP:0100526
      label: Neoplasm of the lung
  evidence:
  - reference: PMID:33446664
    reference_title: "Small-cell lung cancer."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Distinct clinical characteristics of SCLC include the predominantly central location of the primary tumour in the major airways and the often extensive extrapulmonary metastatic spread at presentation."
    explanation: "Supports SCLC presenting as a centrally located primary lung mass with extensive intrathoracic/mediastinal spread; peripheral nodules are rare."
- category: Clinical
  name: Smoking Association
  frequency: VERY_FREQUENT
  description: >-
    SCLC is strongly associated with tobacco smoking, with >95% of patients
    having smoking history. SCLC rarely occurs in never-smokers.
  phenotype_term:
    preferred_term: Neoplasm of the lung
    term:
      id: HP:0100526
      label: Neoplasm of the lung
  evidence:
  - reference: PMID:33446664
    reference_title: "Small-cell lung cancer."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "SCLC is strongly associated with smoking, with 98% of cases arising in current or former smokers"
    explanation: "Supports the dominant tobacco-smoking risk-factor association for SCLC, with the vast majority of cases occurring in current or former smokers."
- category: Clinical
  name: Brain Metastases
  frequency: VERY_FREQUENT
  description: >-
    Brain metastases are extremely common in SCLC, occurring in up to 50-80%
    of patients during disease course. Prophylactic cranial irradiation (PCI)
    may reduce this risk in responders.
  phenotype_term:
    preferred_term: Neoplasm of the nervous system
    term:
      id: HP:0004375
      label: Neoplasm of the nervous system
  evidence:
  - reference: PMID:17699816
    reference_title: "Prophylactic cranial irradiation in extensive small-cell lung cancer."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The cumulative risk of brain metastases within 1 year was 14.6% in the irradiation group (95% CI, 8.3 to 20.9) and 40.4% in the control group"
    explanation: "Randomized trial quantifies the high incidence of brain metastases in extensive SCLC and shows prophylactic cranial irradiation substantially reduces this risk in responders."
- category: Clinical
  name: Paraneoplastic Syndromes
  frequency: OCCASIONAL
  description: >-
    SCLC commonly produces paraneoplastic syndromes including SIADH (hyponatremia),
    Cushing syndrome (ectopic ACTH), Lambert-Eaton myasthenic syndrome (anti-VGCC
    antibodies), and limbic encephalitis (anti-Hu antibodies).
  phenotype_term:
    preferred_term: Neoplasm of the lung
    term:
      id: HP:0100526
      label: Neoplasm of the lung
  evidence:
  - reference: PMID:33209464
    reference_title: "Paraneoplastic syndromes in small cell lung cancer."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Paraneoplastic syndromes can commonly occur due to lung cancer, especially small cell lung cancer."
    explanation: "Review establishes SCLC as the classic cause of paraneoplastic syndromes (endocrine syndromes such as SIADH/ectopic ACTH and antibody-mediated neurologic syndromes such as Lambert-Eaton)."
biochemical:
- name: Neuroendocrine Markers
  notes: >-
    SCLC expresses neuroendocrine markers: synaptophysin, chromogranin A, and
    CD56 (NCAM). At least one marker is typically positive. TTF-1 is also
    frequently positive. Ki-67 proliferation index is typically very high (>50%).
  evidence:
  - reference: PMID:33687006
    reference_title: "Clinicopathological and immunohistochemical study of pulmonary neuroendocrine tumors - A single-institute experience."
    supports: SUPPORT
    snippet: "markers which included synaptophysin, chromogranin, CD56"
    explanation: "Pulmonary neuroendocrine tumor study notes diagnostic IHC panel includes classic neuroendocrine markers used for SCLC."
prevalence:
- population: United States
  measure_type: ANNUAL_INCIDENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 4.6
  notes: >-
    SEER age-adjusted incidence rate, 2020 (declined from 9 per 100,000 in 2000,
    ~3% average annual decrease, paralleling reduced smoking rates).
  evidence:
  - reference: PMID:39908169
    reference_title: "Trends in the Incidence and Survival Outcomes in Patients With Small Cell Lung Cancer in the United States: An Analysis of the SEER Database."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "from 9 per 100,000 in 2000 to 4.6 per 100,000 in 2020"
    explanation: "SEER analysis of 188,426 US SCLC patients reports the age-adjusted incidence declined to 4.6 per 100,000 in 2020."
genetic:
- name: TP53
  gene_term:
    preferred_term: TP53
    term:
      id: hgnc:11998
      label: TP53
  association: Somatic Inactivating Mutation
  inheritance:
  - name: Somatic
  notes: >-
    TP53 (17p13.1) is inactivated in >90% of SCLC through biallelic mutations
    or deletions. Loss of p53 is considered a defining feature of SCLC.
    Combined with RB1 loss, this creates the aggressive phenotype.
  evidence:
  - reference: PMID:38473726
    reference_title: "P53 and Rb Aberrations in Small Cell Lung Cancer (SCLC): From Molecular Mechanisms to Therapeutic Modulation."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The genes coding for the tumor suppressors p53 and retinoblastoma (Rb) are inactivated in the vast majority of small cell lung cancer (SCLC) tumors."
    explanation: Documents near-universal TP53 (p53) inactivation in SCLC.
- name: RB1
  gene_term:
    preferred_term: RB1
    term:
      id: hgnc:9884
      label: RB1
  association: Somatic Inactivating Mutation
  inheritance:
  - name: Somatic
  notes: >-
    RB1 (13q14.2) is inactivated in >90% of SCLC through biallelic mutations
    or deletions. Combined TP53/RB1 loss is essentially universal in SCLC
    and serves as a molecular definition of the disease.
  evidence:
  - reference: PMID:38473726
    reference_title: "P53 and Rb Aberrations in Small Cell Lung Cancer (SCLC): From Molecular Mechanisms to Therapeutic Modulation."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Data support the notion that these two deleterious genetic events represent the initial steps in the development of SCLC"
    explanation: Documents RB1 (Rb) loss, alongside TP53, as an initiating genetic event essentially universal in SCLC.
- name: MYC
  gene_term:
    preferred_term: MYC
    term:
      id: hgnc:7553
      label: MYC
  association: Amplification
  inheritance:
  - name: Somatic
  notes: >-
    MYC family amplification (MYC, MYCL, MYCN) occurs in ~20% of SCLC.
    MYC amplification is associated with variant histology and worse prognosis.
    May predict response to certain therapeutic approaches (Aurora kinase
    inhibitors, chemotherapy timing).
- name: NOTCH
  association: Somatic Inactivating Mutation
  inheritance:
  - name: Somatic
  notes: >-
    NOTCH family members (especially NOTCH1) are inactivated in ~25% of SCLC.
    NOTCH normally suppresses neuroendocrine differentiation; its loss promotes
    the neuroendocrine phenotype.
treatments:
- name: Platinum-Etoposide Chemotherapy
  description: >-
    Carboplatin or cisplatin plus etoposide is the backbone of SCLC treatment.
    High initial response rates (60-80%) but nearly universal relapse. Four
    cycles is standard for extensive-stage; concurrent with radiation for
    limited-stage.
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: NCIT:C15632
      label: Chemotherapy
  evidence:
  - reference: PMID:40843764
    reference_title: Current and Emerging Therapeutic Strategies for Limited- and Extensive-Stage Small-Cell Lung Cancer.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "For ES-SCLC, the treatment paradigm has been fundamentally transformed by the integration of immune checkpoint inhibitors (ICIs) with platinum-etoposide chemotherapy, establishing a new standard of care"
    explanation: Integration of immune checkpoint inhibitors with platinum-etoposide chemotherapy is the standard-of-care backbone for extensive-stage SCLC.
- name: Atezolizumab (with Chemotherapy)
  description: >-
    PD-L1 checkpoint inhibitor added to carboplatin-etoposide for extensive-stage
    SCLC. IMpower133 trial showed modest overall survival benefit. Now standard
    first-line for extensive-stage.
  treatment_term:
    preferred_term: immunotherapy
    term:
      id: NCIT:C15262
      label: Immunotherapy
    therapeutic_agent:
    - preferred_term: atezolizumab
      term:
        id: NCIT:C106250
        label: Atezolizumab
- name: Durvalumab (with Chemotherapy)
  description: >-
    PD-L1 checkpoint inhibitor added to platinum-etoposide for extensive-stage
    SCLC. CASPIAN trial showed overall survival benefit. Alternative to
    atezolizumab-based regimen.
  treatment_term:
    preferred_term: immunotherapy
    term:
      id: NCIT:C15262
      label: Immunotherapy
    therapeutic_agent:
    - preferred_term: durvalumab
      term:
        id: NCIT:C103194
        label: Durvalumab
- name: Thoracic Radiation
  description: >-
    Concurrent thoracic radiation with chemotherapy for limited-stage SCLC.
    Essential component of potentially curative therapy. Consolidative thoracic
    radiation may also benefit select extensive-stage patients.
  therapeutic_modality: RADIOTHERAPY
  treatment_term:
    preferred_term: radiation therapy
    term:
      id: NCIT:C15313
      label: Radiation Therapy
- name: Prophylactic Cranial Irradiation
  description: >-
    Whole-brain radiation to prevent brain metastases in responding patients.
    Reduces brain metastasis incidence but controversial due to neurocognitive
    effects. Alternative is surveillance with MRI.
  therapeutic_modality: RADIOTHERAPY
  treatment_term:
    preferred_term: radiation therapy
    term:
      id: NCIT:C15313
      label: Radiation Therapy
- name: Lurbinectedin
  description: >-
    Transcription inhibitor approved for relapsed SCLC. Alternative to topotecan
    for second-line treatment. Works by inhibiting oncogenic transcription
    factors.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: lurbinectedin
      term:
        id: CHEBI:746908
        label: lurbinectedin
- name: Topotecan
  description: >-
    Topoisomerase I inhibitor used for relapsed SCLC. Standard second-line
    option, though responses are generally modest and short-lived.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: topotecan
      term:
        id: CHEBI:63632
        label: topotecan
- name: Tarlatamab
  description: >-
    DLL3-directed bispecific T-cell engager (DLL3 x CD3 BiTE) that redirects
    T cells against the neuroendocrine-lineage surface antigen DLL3, which is
    highly expressed in SCLC. FDA-approved in 2024 for relapsed/refractory
    extensive-stage SCLC. Represents the most clinically advanced DLL3-targeted
    immunotherapy.
  therapeutic_modality: MONOCLONAL_ANTIBODY
  treatment_term:
    preferred_term: immunotherapy
    term:
      id: NCIT:C15262
      label: Immunotherapy
    therapeutic_agent:
    - preferred_term: tarlatamab
      term:
        id: NCIT:C175858
        label: Tarlatamab
  evidence:
  - reference: PMID:38630789
    reference_title: "Facts and Hopes on Cancer Immunotherapy for Small Cell Lung Cancer."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "delta-like ligand 3-targeted bispecific T-cell engagers have shown the most compelling preliminary evidence of clinical efficacy"
    explanation: "Immunotherapy review highlights DLL3-targeted bispecific T-cell engagers (tarlatamab) as the most clinically promising emerging immunotherapy for SCLC."
  - reference: PMID:37627044
    reference_title: "Small Cell Lung Cancer: Emerging Targets and Strategies for Precision Therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The potential of targeting DLL3, a NOTCH ligand, through antibody-drug conjugates, bispecific T-cell engagers, and CAR T-cell therapy"
    explanation: "Precision-therapy review identifies DLL3 as a key SCLC surface target for bispecific T-cell engagers, ADCs, and CAR-T approaches."
- name: Benmelstobart plus Anlotinib with Chemotherapy
  description: >-
    First-line extensive-stage SCLC regimen adding the PD-L1 inhibitor
    benmelstobart and the multi-target anti-angiogenic small molecule anlotinib
    to etoposide/carboplatin (ETER701 trial). This immunochemotherapy plus
    anti-angiogenesis combination achieved a median overall survival of 19.3
    months, greater than in prior randomized ES-SCLC studies.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: benmelstobart
      term:
        id: NCIT:C156692
        label: Benmelstobart
    - preferred_term: anlotinib
      term:
        id: NCIT:C138997
        label: Catequentinib
  evidence:
  - reference: PMID:38992123
    reference_title: "Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "median OS was prolonged with benmelstobart and anlotinib plus EC"
    explanation: "Randomized phase 3 ETER701 trial shows adding benmelstobart (PD-L1 inhibitor) plus anlotinib (anti-angiogenic) to etoposide/carboplatin prolongs overall survival in extensive-stage SCLC."
disease_term:
  preferred_term: small cell lung carcinoma
  term:
    id: MONDO:0008433
    label: small cell lung carcinoma

gene_sets:
- gene_set: MYGENESET:KEGG_SMALL_CELL_LUNG_CANCER
  relationship: CANONICAL_PATHWAY
  note: >-
    KEGG small cell lung cancer pathway.
classifications:
  icdo_morphology:
    classification_value: Carcinoma
  harrisons_chapter:
  - classification_value: ONCOLOGY_HEMATOLOGY
datasets:
- accession: ega:EGAS00000000051
  title: A small cell lung cancer genome reports complex tobacco exposure signatures
  description: Cancer is driven by mutation. Worldwide, tobacco smoking is the major lifestyle exposure that causes cancer, exerting carcinogenicity through 60 chemicals that bind and mutate DNA. Using massively parallel sequencing technology, we sequenced a small cell lung cancer cell line, NCI-H209, to explore the mutational burden associated with tobacco smoking. 22,910 somatic substitutions were identified, including 132 in coding exons. Multiple mutation signatures testify to the cocktail of carcinogens in tobacco smoke and their proclivities for particular bases and surrounding sequence context.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: WGS
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Small Cell Lung Cancer"); description-level mentions were not accepted. EGA study_type: Whole Genome Sequencing. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00001000299
  title: Integrative analysis of small cell lung cancer
  description: Small-cell lung cancer (SCLC) is an aggressive lung tumor subtype. We conducted integrated analysis of genome sequencing, transcriptome, and copy number analysis and found an extremely high mutation rate of 7.4±1 protein-changing mutations per million basepairs. Evidence for inactivation of TP53 and RB1 was found in all sequenced cases. Furthermore, we identified recurrent mutations in CREBBP, EP300, and MLL, observed mutations in PTEN, in SLIT2, and EPHA7, as well as focal amplifications of the FGFR1 locus.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  publication: PMID:22941188
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Small Cell Lung Cancer"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00001000334
  title: Genentech Small Cell Lung Cancer (SCLC) Screen
  description: Exome capture, RNA-Seq, whole genome sequencing of set of Small Cell Lung Cancer samples.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  publication: PMID:22941189
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Small Cell Lung Cancer"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: metabolomics_workbench:ST000220
  title: Small cell lung cancer metabolome (part II)
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from metabolomics_workbench. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Small Cell Lung Cancer"). Retrieved 2026-08-02.
- accession: massive:MSV000090746
  title: The NFIB/CARM1 Partnership is a Therapeutic Target for Small Cell Lung Cancer
  description: This project identified NFI family members as CARM1 substrates. NFIB was previously reported to play a critical role in the development of small cell lung cancer. We provided evidence that the arginine methylation of NFIB is required for its oncogenic function in small cell lung cancer.
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Small Cell Lung Cancer"). Retrieved 2026-08-02.
📚

References & Deep Research

Deep Research

1
Falcon ▸
1. Disease Information
Edison Scientific Literature 48 citations 2026-07-05T19:13:52.012141

1. Disease Information

Overview

Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine malignancy accounting for approximately 10–15% of all lung cancers (zugazagoitia2024factsandhopes pages 1-1, redin2024smallcelllung pages 1-3). It is characterized by rapid growth, high metastatic capacity, early dissemination, and a strong epidemiologic and biologic association with tobacco carcinogens (megyesfalvi2023clinicalinsightsinto pages 1-2). Although SCLC is initially highly responsive to platinum-based chemotherapy, these responses are transient, and approximately 90% of patients experience rapid disease recurrence (redin2024smallcelllung pages 1-3). The 5-year survival rate remains dismally low at approximately 5–7% (huang2025molecularsubtypesand pages 1-2, redin2024smallcelllung pages 1-3).

Key Identifiers

  • MONDO ID: MONDO:0008433 (small cell lung carcinoma) (OpenTargets Search: small cell lung cancer)
  • ICD-10: C34 (malignant neoplasm of bronchus and lung; SCLC specified as small cell carcinoma)
  • ICD-O-3 Morphology: 8041/3 (small cell carcinoma, NOS)
  • MeSH: D055752 (Small Cell Lung Carcinoma)
  • Orphanet: ORPHA:70573

Synonyms and Alternative Names

Common synonyms include: small cell carcinoma of the lung, oat cell carcinoma, small cell undifferentiated carcinoma, and neuroendocrine carcinoma of the lung (small cell type). SCLC is classified among high-grade pulmonary neuroendocrine neoplasms.

Data Sources

Information in this report is derived from aggregated disease-level resources including comprehensive peer-reviewed reviews, SEER database analyses, clinical trial registries, and the OpenTargets Platform.

2. Etiology

Disease Causal Factors

The dominant causal factor in SCLC is tobacco smoke exposure. SCLC has the strongest epidemiologic link to tobacco carcinogens among all lung cancer subtypes, with the vast majority of patients being current or former heavy smokers (megyesfalvi2023clinicalinsightsinto pages 1-2). Genomically, SCLC is characterized by near-universal inactivation of the tumor suppressor genes TP53 (~92% of cases) and RB1 (~74%), which represent the initial steps in malignant transformation (redin2024smallcelllung pages 1-3). Additional recurrent genetic alterations include inactivating mutations in PTEN, CREBBP, EP300, KMT2D, NOTCH family genes, and activating mutations in PIK3CA (megyesfalvi2023clinicalinsightsinto pages 5-5, OpenTargets Search: small cell lung cancer). MYC family amplification (MYC, MYCL, MYCN) is also frequent (megyesfalvi2023clinicalinsightsinto pages 5-5).

Risk Factors

Genetic risk factors: TP53 and RB1 co-alteration is the defining molecular event essential for SCLC pathogenesis (huang2025molecularsubtypesand pages 1-2, redin2024smallcelllung pages 1-3). An integrative analysis of 3,600 real-world SCLC cases identified new genetic subtypes including STK11-mutant tumors (1.7%) and TP53/RB1 wild-type tumors (5.5%), of which 12.7% were HPV-positive. CCNE1 amplification was associated with decreased overall survival, while 4q12 gene amplifications were associated with increased survival (OpenTargets Search: small cell lung cancer).

Environmental risk factors: Tobacco smoking is the predominant environmental risk factor. Additional environmental exposures including radon gas and air pollution contribute to lung cancer risk (huang2025molecularsubtypesand pages 1-2). The disease predominantly affects elderly male heavy smokers (huang2023incidencesurvivalcomparison pages 1-2).

Protective Factors

Smoking cessation is the primary protective factor. The declining incidence of SCLC in the United States over the past two decades (48.6% decrease from 2000 to 2020) is attributed to reduced smoking rates (uprety2025trendsinthe pages 1-2, uprety2025trendsinthe pages 2-4).

3. Phenotypes

Symptoms and Clinical Signs

SCLC commonly presents with centrally located hilar or mediastinal masses, cough, dyspnea, chest pain, hemoptysis, and weight loss. Due to its rapid doubling time and early metastatic spread, approximately 70–80% of patients present with extensive-stage (metastatic) disease at diagnosis (huang2025molecularsubtypesand pages 1-2, redin2024smallcelllung pages 1-3).

  • HPO: HP:0002094 (Dyspnea), HP:0012735 (Cough), HP:0002105 (Hemoptysis), HP:0001824 (Weight loss)

Paraneoplastic Syndromes

SCLC is notably associated with paraneoplastic syndromes due to its neuroendocrine differentiation. These include: - SIADH (Syndrome of Inappropriate Antidiuretic Hormone secretion) — the most common paraneoplastic syndrome in SCLC - Lambert-Eaton Myasthenic Syndrome (LEMS) — characterized by calcium-channel antibodies (megyesfalvi2023clinicalinsightsinto pages 27-27) - Cushing syndrome — ectopic ACTH production - Anti-Hu antibody-related paraneoplastic syndromes — presenting with progressive dysautonomia and neuropathy (megyesfalvi2023clinicalinsightsinto pages 27-27)

Patients with neurologic paraneoplastic syndromes have been associated with improved prognosis and increased tumor-infiltrating lymphocytes (megyesfalvi2023clinicalinsightsinto pages 27-27).

Quality of Life Impact

SCLC profoundly impacts quality of life through rapid symptom progression, metastatic disease burden (particularly brain metastases), and treatment-related toxicity. The aggressive disease course and short survival significantly affect functional status and psychosocial well-being.

4. Genetic/Molecular Information

Causal Genes and Pathogenic Variants

The genes coding for the tumor suppressors p53 (TP53) and retinoblastoma (RB1) are inactivated in the vast majority of SCLC tumors. These two deleterious genetic events represent the initial steps in SCLC development, making them essential for a lung epithelial cell to progress toward malignancy (huang2025molecularsubtypesand pages 1-2, megyesfalvi2023clinicalinsightsinto pages 1-2). TP53 is mutated in approximately 92% of cases and RB1 in approximately 74% (redin2024smallcelllung pages 1-3).

Additional recurrently altered genes include: - PTEN (pathway: PI3K-AKT-mTOR) — more frequent alterations in brain metastases (OpenTargets Search: small cell lung cancer) - CREBBP and EP300 — chromatin remodeling/histone acetyltransferase genes (OpenTargets Search: small cell lung cancer) - KMT2D — lysine methyltransferase involved in epigenetic regulation (OpenTargets Search: small cell lung cancer) - NOTCH family genes — tumor suppressive role in NE lineage (megyesfalvi2023clinicalinsightsinto pages 5-5) - PIK3CA — activating mutations (megyesfalvi2023clinicalinsightsinto pages 5-5) - MYC/MYCL/MYCN — amplifications driving aggressive phenotype (megyesfalvi2023clinicalinsightsinto pages 5-5) - SMARCA4 — catalytic subunit of SWI/SNF complex, mutations in 1.5–4% of cases (redin2024smarca4controlsstate pages 1-2) - KEAP1 — may contribute to SCLC pathogenesis (OpenTargets Search: small cell lung cancer)

Molecular Subtypes

Recent multi-omic studies have revealed distinct molecular subtypes driven by lineage-defining transcription factors (huang2025molecularsubtypesand pages 1-2, redin2024smallcelllung pages 1-3):

Subtype Transcription factor / defining program Approx. frequency Neuroendocrine status Key molecular features / pathway enrichment Suggested targeted therapies / vulnerabilities
SCLC-A ASCL1 ~70% NE-high Canonical neuroendocrine subtype; enriched for BCL2, DLL3, SOX2, RET, MYCL1 and ASCL1-driven lineage programs (redin2024smallcelllung pages 1-3, huang2025molecularsubtypesand pages 7-9, huang2025molecularsubtypesand pages 2-4) DLL3-targeting agents (e.g., tarlatamab), BCL2 inhibitors (venetoclax), LSD1 inhibitors, HDAC inhibitors; RET/BCL2-directed strategies under study (huang2025molecularsubtypesand pages 7-9, patel2023smallcelllung pages 1-2)
SCLC-N NEUROD1 ~15% NE-high More aggressive/proliferative state; associated with MYC co-expression/amplification, neuronal signaling, chemoresistance, and elevated AURKA/AURKB dependence (redin2024smallcelllung pages 1-3, huang2025molecularsubtypesand pages 7-9, huang2025molecularsubtypesand pages 2-4) Aurora kinase inhibitors (e.g., alisertib), MYC-directed approaches, cell-cycle pathway targeting; IMPDH inhibitors proposed in review literature (huang2025molecularsubtypesand pages 7-9, huang2025molecularsubtypesand pages 2-4)
SCLC-P POU2F3 7–15% NE-low / non-NE Tuft-cell-like subtype; depends on IGF1R signaling and shows relative DNA repair deficiencies; transcriptomically distinct from classic NE SCLC (redin2024smallcelllung pages 1-3, huang2025molecularsubtypesand pages 2-4, redin2024smallcelllung pages 4-6) IGF1R inhibitors, PARP inhibitors, DNA-damaging agents, SWI/SNF ATPase-directed approaches proposed for selected tumors (huang2025molecularsubtypesand pages 7-9, huang2025molecularsubtypesand pages 2-4)
SCLC-Y YAP1 (debated as stable subtype in some studies) 3–10% NE-low / non-NE Linked to low-NE state, lineage plasticity, EMT/non-NE features, and therapy resistance; YAP/Notch/REST programs implicated. Some reviews note this category is biologically less stable or inconsistently reproduced across datasets (redin2024smallcelllung pages 1-3, huang2025molecularsubtypesand pages 2-4, redin2024smallcelllung pages 11-13, redin2024smallcelllung pages 13-14) No single standard targeted therapy; candidate approaches include ERBB pathway targeting in specific low-NE/YAP-associated transitions and broader plasticity-directed/epigenetic strategies (huang2025molecularsubtypesand pages 13-15, redin2024smarca4controlsstate pages 1-2, redin2024smallcelllung pages 13-14)
SCLC-I Inflamed / immune program rather than dominant ASCL1/NEUROD1/POU2F3 Not firmly fixed; distinct subset Often NE-low / inflamed Characterized by inflamed gene signatures, higher HLA/antigen-presentation, immune checkpoint expression, mesenchymal features, and greater immune-cell infiltration versus NE-high “immune desert” tumors (zugazagoitia2024factsandhopes pages 1-1, megyesfalvi2023clinicalinsightsinto pages 6-7) Greatest rationale for immune checkpoint blockade; biomarker-enriched immunotherapy strategies and combination immunotherapy approaches are emphasized (zugazagoitia2024factsandhopes pages 1-1, chen2024advancesinpredictive pages 2-4, megyesfalvi2023clinicalinsightsinto pages 6-7)

Table: This table summarizes the main molecular subtypes of small cell lung cancer, their defining transcriptional programs, approximate frequencies, biologic features, and leading therapeutic hypotheses. It is useful for mapping subtype biology to emerging precision-treatment strategies.

Epigenetic Information

Epigenetic regulation plays a critical role in SCLC biology. SMARCA4, the catalytic subunit of the SWI/SNF chromatin remodeling complex, controls neuroendocrine state plasticity by binding to ASCL1 and NEUROD1 gene loci and enhancing chromatin accessibility (redin2024smarca4controlsstate pages 1-2). State transitions in SCLC appear to be epigenetically rather than mutationally determined, with SMARCA4 inhibition inducing loss of NE features and activation of non-NE signaling pathways (redin2024smarca4controlsstate pages 1-2). DNA methylation patterns correlate with EZH2 expression and define clinically relevant subtypes (redin2024smallcelllung pages 11-13). CREBBP loss sensitizes tumors to HDAC inhibition (redin2024smallcelllung pages 13-14).

5. Environmental Information

Environmental and Lifestyle Factors

Tobacco smoking is the dominant environmental risk factor, with SCLC having the strongest association with tobacco carcinogens among lung cancer subtypes (megyesfalvi2023clinicalinsightsinto pages 1-2). The declining incidence of SCLC directly parallels declining smoking rates in the United States, with the age-adjusted incidence rate dropping from 9 per 100,000 in 2000 to 4.6 per 100,000 in 2020 (uprety2025trendsinthe pages 1-2). Additional environmental exposures including radon gas and air pollution contribute to lung carcinogenesis risk (huang2025molecularsubtypesand pages 1-2).

Infectious Agents

While not a primary etiologic factor, HPV-positive SCLC has been identified in a subset of TP53/RB1 wild-type tumors, with 12.7% of this uncommon genotype testing HPV-positive (OpenTargets Search: small cell lung cancer).

6. Mechanism / Pathophysiology

Molecular Pathways

SCLC pathogenesis involves multiple interconnected signaling cascades: - TP53/RB1 inactivation pathway: Near-universal loss of both tumor suppressors eliminates cell cycle control and senescence barriers, enabling indefinite proliferation (papavassiliou2024p53andrb pages 4-5) - MYC signaling: MYC amplification drives NE-low phenotype with high NEUROD1 expression and promotes subtype transition from SCLC-A to SCLC-N (megyesfalvi2023clinicalinsightsinto pages 5-5) - Notch signaling: Activated by MYC, mediates NE plasticity and lineage switching (megyesfalvi2023clinicalinsightsinto pages 5-5) - BCL2 anti-apoptotic pathway: Elevated BCL2 expression is a transcriptional target of ASCL1, suppressing apoptosis (megyesfalvi2023clinicalinsightsinto pages 5-5) - PI3K-AKT-mTOR pathway: PTEN deletions and PIK3CA mutations activate this pro-survival cascade (megyesfalvi2023clinicalinsightsinto pages 5-5) - YAP/Notch/REST network: Controls neuroendocrine cell fate determination (redin2024smallcelllung pages 11-13)

GO Terms: GO:0008283 (cell population proliferation), GO:0006915 (apoptotic process), GO:0007219 (Notch signaling pathway)

Cellular Processes and Cell Types

SCLC can arise from multiple pulmonary cell types including basal cells, neuroendocrine cells, club cells, and alveolar type 2 (AT2) cells (redin2024smallcelllung pages 4-6). The SCLC-P subtype shows transcriptomic similarity to tuft cells, suggesting tuft cell precursors as a possible origin (redin2024smallcelllung pages 4-6). Neuroendocrine cells of the lung are characterized by dense-core granules and NE marker expression (megyesfalvi2023clinicalinsightsinto pages 5-5).

CL terms: CL:1000223 (lung neuroendocrine cell), CL:0000083 (epithelial cell of lung), CL:0002063 (type II pneumocyte)

Immune Evasion Mechanisms

SCLC employs multiple immune evasion strategies: - T cell exclusion: NE-high SCLCs are characterized as "immune desert" tumors with minimal infiltrating immune cells (megyesfalvi2023clinicalinsightsinto pages 6-7) - MHC-class I downregulation: Reduced antigen processing and presentation machinery (zugazagoitia2024factsandhopes pages 1-1) - Surface glycolipid/glycoprotein overexpression: GD2 ganglioside engages siglec7 on macrophages and NK cells to suppress immunity (zugazagoitia2024factsandhopes pages 2-3) - CD47 overexpression: Inhibits macrophage-mediated phagocytosis through SIRPα binding (zugazagoitia2024factsandhopes pages 2-3) - PD-L1 upregulation: T-cell checkpoint immune inhibitory signaling (zugazagoitia2024factsandhopes pages 2-3)

Tumor Microenvironment

The SCLC tumor microenvironment is characterized by abundant, aggressively growing cancer cells that vastly outnumber immune cells, with minimal interdigitated tumor-associated immune stroma (zugazagoitia2024factsandhopes pages 2-3). However, the SCLC-I (inflamed) subtype demonstrates higher immune-cell infiltration, elevated checkpoint and HLA expression, and greater potential benefit from immunotherapy (megyesfalvi2023clinicalinsightsinto pages 6-7).

7. Anatomical Structures Affected

Primary Organs

  • Lung (UBERON:0002048) — primary site; tumors typically arise centrally in hilar/mediastinal regions
  • Brain — frequent metastatic site; contrast-enhanced MRI is standard for evaluation (megyesfalvi2023clinicalinsightsinto pages 10-11)
  • Liver — common metastatic site; liver metastasis is most common distant site in SCLC (OpenTargets Search: small cell lung cancer)
  • Bone — frequent metastatic site
  • Adrenal glands — common metastatic site

Tissue and Cell Level

  • Pulmonary neuroendocrine cells (CL:1000223)
  • Small blue cells with scant cytoplasm, hyperchromatic nuclei, and salt-and-pepper chromatin (megyesfalvi2023clinicalinsightsinto pages 10-11)
  • Dense-core neurosecretory granules (ultrastructural hallmark)

8. Temporal Development

Onset

SCLC predominantly affects adults aged 60–80 years, with the disease being rare in patients under 40. The peak incidence is in the seventh decade of life (huang2023incidencesurvivalcomparison pages 1-2). Onset is typically subacute to acute, with rapid symptom progression over weeks to months.

Progression and Staging

SCLC is staged using two systems: 1. Veterans Affairs Lung Study Group (VALSG): Limited-stage (LS-SCLC, ~30% of patients) vs. Extensive-stage (ES-SCLC, ~70% of patients) (huang2025molecularsubtypesand pages 1-2, redin2024smallcelllung pages 1-3) 2. AJCC TNM staging system: Increasingly used for prognostic refinement

Disease progression is extremely rapid, with a median doubling time of approximately 30 days. Despite high initial chemosensitivity, drug resistance develops rapidly, and recurrence occurs in the majority of patients (megyesfalvi2023clinicalinsightsinto pages 1-2).

Disease Course

  • LS-SCLC: Median survival 15–20 months with chemoradiation; 5-year survival 20–25% (chen2024aretrospectivestudy pages 1-2)
  • ES-SCLC: Median survival historically ~10 months with chemotherapy; improved to 12–13 months with immunotherapy addition, and up to 19.3 months with anti-angiogenic combination regimens (chen2024advancesinpredictive pages 2-4, cheng2024benmelstobartanlotiniband pages 1-2)

9. Inheritance and Population

Epidemiology

SCLC is not a heritable Mendelian disorder but rather a sporadic malignancy driven by somatic mutations accumulated through carcinogenic exposure.

Incidence: A comprehensive SEER database analysis of 188,426 SCLC patients (2000–2020) demonstrated that the age-adjusted incidence rate declined by an average of 3% annually, from 9 per 100,000 in 2000 to 4.6 per 100,000 in 2020 — a 48.6% overall decrease (uprety2025trendsinthe pages 1-2, uprety2025trendsinthe pages 2-4). In 2023, there were approximately 238,340 new lung cancer cases in the United States, with SCLC comprising approximately 13% (chen2024aretrospectivestudy pages 1-2).

Population Demographics: - Incidence declines were observed across all age groups, sexes, and races, with younger groups (<50 years) showing sharper declines (APC -6.4%) compared to older populations (80+, APC -1.6%) (uprety2025trendsinthe pages 2-4) - Males experienced steeper incidence declines (-3.5% APC) than females (-2.5% APC) (uprety2025trendsinthe pages 2-4) - The disease predominantly affects elderly male heavy smokers (huang2023incidencesurvivalcomparison pages 1-2) - Five-year overall survival remains less than 10–15% across all stages (chen2024aretrospectivestudy pages 1-2, huang2023incidencesurvivalcomparison pages 1-2)

Survival trends: Despite declining incidence and incidence-based mortality (from 6.6 in 2005 to 3.5 in 2020), 1-year relative survival rates have not improved significantly over the two-decade period, indicating the need for more effective systemic therapies (uprety2025trendsinthe pages 1-2).

10. Diagnostics

Clinical Tests and Imaging

  • Chest radiography: Initial imaging; may be unremarkable in ~4% of SCLC patients (megyesfalvi2023clinicalinsightsinto pages 9-9)
  • Contrast-enhanced CT: Chest and upper abdomen for evaluating local invasiveness and staging (megyesfalvi2023clinicalinsightsinto pages 9-9)
  • 18F-FDG PET-CT: Key diagnostic tool demonstrating intense uptake due to SCLC's high metabolic activity; also helps estimate prognosis — higher metabolic tumor burden and total lesion glycolysis are associated with poor prognosis (megyesfalvi2023clinicalinsightsinto pages 9-9)
  • Contrast-enhanced brain MRI: Standard for evaluating brain metastases (megyesfalvi2023clinicalinsightsinto pages 10-11)
  • Gallium-68 dotatate PET-CT: For tumors with high somatostatin receptor expression (megyesfalvi2023clinicalinsightsinto pages 9-9)

Tissue Diagnosis

  • Flexible bronchoscopy: Preferred for centrally located tumors (megyesfalvi2023clinicalinsightsinto pages 10-10)
  • Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA): For peribronchial tumors and mediastinal lymph node staging (megyesfalvi2023clinicalinsightsinto pages 10-10, megyesfalvi2023clinicalinsightsinto pages 10-11)
  • CT-guided transthoracic needle biopsy: Sensitivity exceeding 90% for peripheral lesions (megyesfalvi2023clinicalinsightsinto pages 10-10)

Pathology

Characteristic cytologic findings include small blue cells approximately 1.5 times the size of lymphocytes with scant cytoplasm, hyperchromatic oval or elongated nuclei with well-developed nuclear molding, and a finely dispersed "salt and pepper" chromatin pattern (megyesfalvi2023clinicalinsightsinto pages 10-11).

Biomarkers

  • Neuroendocrine markers: Synaptophysin, chromogranin A, CD56 (NCAM)
  • Transcription factor-based subtyping: ASCL1, NEUROD1, POU2F3, YAP1 (IHC and RNA-based)
  • PD-L1 expression: Evaluated but inconsistent as predictive biomarker for immunotherapy response (chen2024advancesinpredictive pages 2-4)
  • Tumor mutational burden (TMB): Exploratory predictive biomarker (chen2024advancesinpredictive pages 2-4)
  • SLFN11 expression: Predictive biomarker for PARP inhibitor sensitivity (huang2025molecularsubtypesand pages 7-9)
  • Circulating tumor DNA (ctDNA): Emerging role in diagnosis and dynamic monitoring (megyesfalvi2023clinicalinsightsinto pages 10-10, chen2024advancesinpredictive pages 2-4)
  • Circulating tumor cells (CTCs): Potential for liquid biopsy diagnosis (chen2024advancesinpredictive pages 2-4)

11. Outcome/Prognosis

Survival and Mortality

  • Overall 5-year survival: <7–10% across all stages (huang2025molecularsubtypesand pages 1-2, redin2024smallcelllung pages 1-3, chen2024aretrospectivestudy pages 1-2)
  • LS-SCLC 5-year survival: 20–25% with concurrent chemoradiation (chen2024aretrospectivestudy pages 1-2)
  • ES-SCLC median OS with chemotherapy alone: ~10–11.9 months (bonanno2024realworldimpactof pages 1-2, cheng2024benmelstobartanlotiniband pages 1-2)
  • ES-SCLC median OS with chemoimmunotherapy: 12.3 months (atezolizumab, IMpower133) to 12.9 months (durvalumab, CASPIAN) (chen2024advancesinpredictive pages 2-4)
  • ES-SCLC 3-year survival with chemoimmunotherapy: ~17.6% (CASPIAN) vs. ~5.8% with chemotherapy alone (zugazagoitia2024factsandhopes pages 3-3)
  • ES-SCLC 5-year survival with atezolizumab: 12.1% (IMpower133 extension) (zugazagoitia2024factsandhopes pages 3-3)
  • ES-SCLC with benmelstobart + anlotinib + chemo (ETER701): Median OS 19.3 months — the highest recorded in a randomized trial (cheng2024benmelstobartanlotiniband pages 1-2)

Prognostic Factors

Age, sex, disease stage (TNM), T stage, N stage, M stage, liver metastasis, brain metastasis, bone metastasis, and treatment modality are independent prognostic factors (huang2023incidencesurvivalcomparison pages 1-2). CCNE1 amplification is associated with decreased survival, while 4q12 amplifications are associated with improved survival (OpenTargets Search: small cell lung cancer). Patients with neurologic paraneoplastic syndromes show improved prognosis (megyesfalvi2023clinicalinsightsinto pages 27-27).

12. Treatment

Disease-Target Associations (OpenTargets)

The following table summarizes the key therapeutic targets identified from OpenTargets (MONDO:0008433) and the supporting literature:

Target Gene Symbol Target Name Association Score Key Evidence (approved drugs, clinical stage, relevant PMIDs) Role in SCLC
RB1 RB transcriptional corepressor 1 0.73 OpenTargets lists 5 supporting evidence items for MONDO_0008433, including literature PMIDs 34430610, 35792876, 26168399, 22941188, 24071849; recurrently identified as a defining SCLC tumor suppressor alteration (OpenTargets Search: small cell lung cancer, megyesfalvi2023clinicalinsightsinto pages 1-2) Core tumor suppressor; near-universal functional loss helps drive cell-cycle deregulation and lineage transformation in SCLC (OpenTargets Search: small cell lung cancer, megyesfalvi2023clinicalinsightsinto pages 1-2)
TOP1 DNA topoisomerase I 0.65 OpenTargets includes approval-stage evidence and clinical report IDs linked to TOP1-directed therapy plus regulatory records; literature and clinical evidence support topoisomerase-targeting treatment relevance in SCLC (OpenTargets Search: small cell lung cancer, patel2023smallcelllung pages 1-2) Therapeutic target class rather than lineage driver; relevant because SCLC is highly chemotherapy-sensitive initially and topoisomerase-directed agents are part of the treatment landscape, including irinotecan-based regimens and lurbinectedin-era development context (OpenTargets Search: small cell lung cancer, patel2023smallcelllung pages 1-2)
TP53 Tumor protein p53 0.63 OpenTargets lists 5 evidence items including PMIDs 35340160, 37534137, 40113013, 30279957, 31737176; repeatedly described as nearly universal inactivation in SCLC (OpenTargets Search: small cell lung cancer, megyesfalvi2023clinicalinsightsinto pages 1-2) Foundational tumor suppressor loss; with RB1 inactivation it is a hallmark initiating event in most SCLC and underlies genomic instability, apoptosis evasion, and aggressive behavior (OpenTargets Search: small cell lung cancer, megyesfalvi2023clinicalinsightsinto pages 1-2)
CD274 (PD-L1) CD274 molecule 0.62 OpenTargets includes 5 literature-backed evidence items (PMIDs 32773010, 39810133, 38132164, 37040387, 31315783); clinical use supported by atezolizumab and durvalumab with platinum-etoposide in ES-SCLC (OpenTargets Search: small cell lung cancer, chen2024advancesinpredictive pages 2-4, bonanno2024realworldimpactof pages 1-2) Immune checkpoint target; PD-L1-axis blockade is part of current first-line standard therapy for extensive-stage SCLC, though benefits are modest and biomarker performance is imperfect (chen2024advancesinpredictive pages 2-4, bonanno2024realworldimpactof pages 1-2)
CDK6 Cyclin dependent kinase 6 0.62 OpenTargets lists literature PMIDs 39136283 and 35117162 plus approval/phase 4 evidence; CDK4/6 dependency is most relevant in RB1-retained subsets (OpenTargets Search: small cell lung cancer) Cell-cycle kinase target; may represent an actionable vulnerability in uncommon RB1-proficient SCLC tumors rather than classic RB1-null disease (OpenTargets Search: small cell lung cancer)
CDK4 Cyclin dependent kinase 4 0.59 OpenTargets lists literature PMIDs 39136283 and 31199581 plus approval/phase 4 evidence; CDK4/6 inhibitor sensitivity has been linked to RB1-expressing SCLC subsets (OpenTargets Search: small cell lung cancer) Similar to CDK6, supports a precision-medicine niche in RB1-intact SCLC, where CDK4/6 blockade may suppress tumor growth (OpenTargets Search: small cell lung cancer)
DLL3 Delta like canonical Notch ligand 3 0.59 OpenTargets includes literature PMIDs 38468968, 41331586, 31819500, 31452726 and approval-stage evidence; DLL3-targeted BiTE therapy tarlatamab is highlighted in recent SCLC therapeutic reviews and trials (OpenTargets Search: small cell lung cancer, megyesfalvi2023clinicalinsightsinto pages 19-20, zugazagoitia2024factsandhopes pages 7-8) Lineage-associated surface antigen enriched in neuroendocrine SCLC; major emerging therapeutic target for bispecific T-cell engagers, ADCs, and CAR-T approaches (megyesfalvi2023clinicalinsightsinto pages 19-20, zugazagoitia2024factsandhopes pages 7-8)
TOP2A DNA topoisomerase II alpha 0.58 OpenTargets includes literature PMIDs 38806610, 37407689, 39921782 plus approval-stage evidence; mechanistically relevant to etoposide-based therapy backbone in SCLC (OpenTargets Search: small cell lung cancer, patel2023smallcelllung pages 1-2) Cytotoxic therapy target linked to the etoposide backbone of standard treatment; reflects persistent dependence of SCLC management on DNA damage and topoisomerase-directed chemotherapy (OpenTargets Search: small cell lung cancer, patel2023smallcelllung pages 1-2)

Table: This table summarizes the leading OpenTargets disease-target associations for small cell lung cancer (MONDO_0008433) and links them to their clinical or biological roles in SCLC. It is useful for distinguishing foundational drivers such as TP53/RB1 from actionable therapeutic targets such as PD-L1, DLL3, CDK4/6, and topoisomerases.

Standard First-Line Therapy

Limited-Stage SCLC: - Concurrent thoracic radiotherapy with platinum-etoposide chemotherapy (cisplatin or carboplatin plus etoposide) (megyesfalvi2023clinicalinsightsinto pages 1-2) - Prophylactic cranial irradiation (PCI) for responders - MAXO: MAXO:0000058 (chemotherapy), MAXO:0000014 (radiation therapy)

Extensive-Stage SCLC: - Platinum-etoposide chemotherapy combined with anti-PD-L1 immunotherapy (atezolizumab or durvalumab) — current standard of care established by IMpower133 and CASPIAN trials (megyesfalvi2023clinicalinsightsinto pages 1-2, chen2024advancesinpredictive pages 2-4, bonanno2024realworldimpactof pages 1-2) - Atezolizumab + carboplatin/etoposide: median OS 12.3 vs. 10.3 months (chen2024advancesinpredictive pages 2-4) - Durvalumab + platinum/etoposide: median OS 12.9 vs. 10.5 months (chen2024advancesinpredictive pages 2-4) - MAXO: MAXO:0001480 (immune checkpoint inhibitor therapy)

Real-world impact: After introduction of chemo-immunotherapy (May 2020), 12-month OS rate increased from 15% to 28% (p=0.03), and 18-month OS rate from 2.1% to 12% (p=0.009), with reduced hospitalization duration (bonanno2024realworldimpactof pages 1-2, bonanno2024realworldimpactof pages 3-5).

Second-Line and Relapsed SCLC

  • Topotecan: Previously the primary approved option for relapsed SCLC (patel2023smallcelllung pages 1-2)
  • Lurbinectedin: FDA accelerated approval in 2020 with 35% overall response rate (patel2023smallcelllung pages 1-2)
  • Lurbinectedin + atezolizumab: ORR 57.7%, median PFS 4.9 months in immunotherapy-naive patients (zugazagoitia2024factsandhopes pages 5-6)

Emerging Targeted Therapies

DLL3-Targeting Agents: - Tarlatamab (AMG 757): DLL3×CD3 bispecific T-cell engager; achieved 23.4% ORR with median duration of response of 12.3 months in heavily pretreated ES-SCLC (megyesfalvi2023clinicalinsightsinto pages 19-20, zugazagoitia2024factsandhopes pages 7-8). FDA approved for relapsed SCLC in 2024.

Antibody-Drug Conjugates (ADCs): - Ifinatamab deruxtecan (I-DXd): Anti-B7-H3 ADC; 53% response rate in SCLC patients (patel2023smallcelllung pages 6-8) - Sacituzumab govitecan: Anti-TROP2 ADC; 18% ORR, 7.1 month median OS (patel2023smallcelllung pages 6-8)

PARP Inhibitors: - Rucaparib + nivolumab: clinical benefit in 56% of patients, 7.4 months median PFS (megyesfalvi2023clinicalinsightsinto pages 19-20) - Talazoparib + atezolizumab maintenance: modest PFS improvement in SLFN11-positive tumors (zugazagoitia2024factsandhopes pages 5-6)

CDK4/6 Inhibitors: - RB1-proficient SCLC (~14% of cases) shows sensitivity to palbociclib and abemaciclib (OpenTargets Search: small cell lung cancer)

Anti-Angiogenic Combinations: - ETER701: Benmelstobart + anlotinib + etoposide/carboplatin achieved unprecedented median OS of 19.3 months in ES-SCLC (cheng2024benmelstobartanlotiniband pages 1-2, zugazagoitia2024factsandhopes pages 3-3)

Key Clinical Trials

NCT Number Trial Name/Description Phase Status Enrollment Key Intervention
NCT04234607 ETER701: first-line extensive-stage SCLC trial of benmelstobart + anlotinib + etoposide/carboplatin versus comparator arms; reported median OS 19.3 vs 11.9 months for triplet vs chemotherapy alone (cheng2024benmelstobartanlotiniband pages 1-2, zugazagoitia2024factsandhopes pages 3-3) Phase 3 Completed/reported 738 Benmelstobart (PD-L1 inhibitor) + anlotinib + etoposide/carboplatin
NCT02763579 IMpower133: landmark first-line ES-SCLC trial establishing atezolizumab + carboplatin/etoposide as a standard option; median OS 12.3 vs 10.3 months versus placebo + chemotherapy (chen2024advancesinpredictive pages 2-4, bonanno2024realworldimpactof pages 1-2) Phase 3 Completed 403 Atezolizumab + carboplatin + etoposide
NCT03043872 CASPIAN: landmark first-line ES-SCLC trial establishing durvalumab + platinum/etoposide; median OS 12.9 vs 10.5 months versus chemotherapy alone (chen2024advancesinpredictive pages 2-4, bonanno2024realworldimpactof pages 1-2) Phase 3 Completed 805 Durvalumab + etoposide + platinum
NCT03319940 First-in-human tarlatamab (AMG 757) study in relapsed/advanced SCLC and other NECs; established clinical activity for DLL3-targeted BiTE therapy (zugazagoitia2024factsandhopes pages 7-8) Phase 1 Active, not recruiting 269 Tarlatamab monotherapy
NCT05361395 First-line tarlatamab combination trial in ES-SCLC (DeLLphi-305 concept): tarlatamab with carboplatin, etoposide, and PD-L1 inhibitor (sen2024emergingadvancesin pages 1-3) Phase 1 Active, not recruiting 184 Tarlatamab + carboplatin + etoposide + PD-L1 inhibitor
NCT05740566 Phase 3 tarlatamab trial in relapsed SCLC referenced through DLL3/CD3 evidence; major confirmatory randomized program for DLL3-targeted BiTE therapy (OpenTargets Search: small cell lung cancer) Phase 3 Ongoing NR Tarlatamab versus standard therapy
NCT06203210 Phase 3 trial of ifinatamab deruxtecan versus physician’s choice in relapsed SCLC (patel2023smallcelllung pages 6-8, OpenTargets Search: small cell lung cancer) Phase 3 Recruiting 540 Ifinatamab deruxtecan (B7-H3 ADC)
NCT07218146 DLLEVATE: Phase 3 trial of ZL-1310 versus investigator’s choice in relapsed SCLC (OpenTargets Search: small cell lung cancer) Phase 3 Recruiting 480 ZL-1310
NCT06498479 ARTEMIS-008: Phase 3 trial of HS-20093 compared with topotecan in relapsed SCLC (OpenTargets Search: small cell lung cancer) Phase 3 Recruiting 460 HS-20093 versus topotecan
NCT07015892 Dose-escalation radiotherapy in limited-stage SCLC randomized Phase 3 study (OpenTargets Search: small cell lung cancer) Phase 3 Recruiting 300 Dose-escalated thoracic radiotherapy
NCT04402788 RAPTOR: addition of radiation therapy to maintenance atezolizumab in extensive-stage SCLC after chemoimmunotherapy (OpenTargets Search: small cell lung cancer) Phase 2/3 Recruiting 138 Thoracic radiation + atezolizumab

Table: This table summarizes landmark and actively recruiting small cell lung cancer trials identified in the research, spanning chemoimmunotherapy, DLL3-targeted therapy, antibody-drug conjugates, and radiation strategies. It is useful for quickly comparing the current clinical development landscape and the studies that shaped present standards of care.

Telomere-Targeting Approaches

6-Thio-2'-deoxyguanosine (6TdG), currently in phase II clinical trials, is a nucleoside analog preferentially incorporated by telomerase into telomeres, leading to telomere dysfunction. In SCLC preclinical models, low intermittent doses inhibited tumor growth, reduced metastatic burden, depleted cancer-initiating cells, and activated innate and adaptive anti-tumor immune responses through STING signaling (eglenenpolat2024atelomeretargetingdrug pages 1-2).

13. Prevention

Primary Prevention

  • Smoking cessation and prevention remain the most important preventive strategies. The 48.6% decline in SCLC incidence from 2000–2020 directly correlates with reduced smoking rates (uprety2025trendsinthe pages 1-2, uprety2025trendsinthe pages 2-4)
  • Radon mitigation in homes and workplaces
  • Air pollution reduction policies

Secondary Prevention (Screening)

Low-dose CT (LDCT) lung cancer screening programs detect predominantly non-small cell lung cancers. SCLC is less commonly detected by screening due to its rapid growth kinetics and interval presentation. However, broader adoption of LDCT screening may increase early-stage SCLC detection.

Tertiary Prevention

  • Prophylactic cranial irradiation (PCI): Reduces brain metastasis incidence in responding LS-SCLC patients
  • Thoracic radiotherapy consolidation: Addition of TRT showed significant survival benefits in ES-SCLC patients receiving immunotherapy plus chemotherapy (median PFS 10.76 vs. 7.63 months; median OS 21.67 vs. 16.6 months) (OpenTargets Search: small cell lung cancer)

14. Other Species / Natural Disease

SCLC is primarily a human disease and does not commonly occur naturally in other species in an identical form. However, spontaneous neuroendocrine tumors have been reported in rodents and dogs. Comparative pathology studies utilize orthologous genes (murine Trp53 and Rb1) in genetically engineered models to recapitulate human disease features.

15. Model Organisms

Genetically Engineered Mouse Models (GEMMs)

The foundational SCLC GEMM was generated by Meuwissen et al. using lung-specific compound deletion of Trp53 and Rb1 genes, which led to SCLC tumor development resembling human disease. A key finding was the long tumor latent period of 9–12 months after genetic deletion, indicating that secondary oncogenic alterations are required for malignant transformation (papavassiliou2024p53andrb pages 4-5). Additional GEMMs incorporating further genetic aberrations (e.g., Rbl2/p130 deletion, Myc overexpression, Pten deletion) alongside Trp53/Rb1 loss showed shorter latency periods (papavassiliou2024p53andrb pages 4-5).

A GEMM with a mutant c-Myc allele demonstrated tumor progression and metastasis associated with subtype transition from SCLC-A to SCLC-N and low-NE YAP1+ SCLC, modeling the plasticity observed in human disease (redin2024smarca4controlsstate pages 1-2).

Cell Lines

Established SCLC cell lines include mouse-derived lines (984 from Rb/p53 KO mice; RPP from Rb/p130/p53 triple KO) and human lines (H1048, H69, H510, H841) (eglenenpolat2024atelomeretargetingdrug pages 1-2).

Patient-Derived Xenografts (PDXs)

PDX models maintain the molecular and biologic features of original patient tumors and are used for preclinical drug testing. They have been employed for ChIPseq characterization of epigenetic regulators like SMARCA4 and for testing novel therapeutic combinations (redin2024smarca4controlsstate pages 1-2, eglenenpolat2024atelomeretargetingdrug pages 1-2).

Syngeneic and Humanized Models

Syngeneic SCLC models are critical for studying immune responses in vivo and testing immunotherapeutic approaches, including 6TdG studies that demonstrated immune-dependent anti-tumor activity (eglenenpolat2024atelomeretargetingdrug pages 1-2).

Model Limitations

  • Long latency periods in GEMMs (9–12 months) limit throughput
  • In vitro TP53/RB1-null cells demonstrate indefinite proliferation but not spontaneous malignant transformation, representing a precancerous state rather than fully malignant SCLC (papavassiliou2024p53andrb pages 4-5)
  • PDX models lack an intact immune system (requiring humanized mouse approaches)
  • Cell line models may not capture the full intratumoral heterogeneity and plasticity of patient tumors
  • Single-biopsy molecular classification may miss intratumoral subtype mixing (redin2024smallcelllung pages 4-6)

Summary

Small cell lung cancer remains one of the most challenging malignancies in oncology, defined by its aggressive biology, near-universal TP53/RB1 inactivation, and rapid chemoresistance development. The molecular reclassification into transcription factor-defined subtypes (SCLC-A, SCLC-N, SCLC-P, SCLC-Y/I) has opened new avenues for precision medicine (huang2025molecularsubtypesand pages 1-2, redin2024smallcelllung pages 1-3). While chemo-immunotherapy has become the standard of care for ES-SCLC with modest survival improvements, emerging therapies including DLL3-targeting bispecific T-cell engagers (tarlatamab), antibody-drug conjugates, and anti-angiogenic combinations (ETER701) show promising activity (megyesfalvi2023clinicalinsightsinto pages 19-20, zugazagoitia2024factsandhopes pages 7-8, cheng2024benmelstobartanlotiniband pages 1-2). The integration of multi-omic data, dynamic liquid biopsy monitoring, and subtype-specific therapeutic strategies represents the future direction for improving outcomes in this devastating disease (huang2025molecularsubtypesand pages 13-15).

References

  1. (zugazagoitia2024factsandhopes pages 1-1): Jon Zugazagoitia, Handerson Osma, Javier Baena, Alvaro C. Ucero, and Luis Paz-Ares. Facts and hopes on cancer immunotherapy for small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 30:2872-2883, Apr 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-1159, doi:10.1158/1078-0432.ccr-23-1159. This article has 29 citations.

  2. (redin2024smallcelllung pages 1-3): Esther Redin, Álvaro Quintanal-Villalonga, and Charles M. Rudin. Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity. Trends in Cancer, 10:935-946, Oct 2024. URL: https://doi.org/10.1016/j.trecan.2024.07.008, doi:10.1016/j.trecan.2024.07.008. This article has 47 citations and is from a peer-reviewed journal.

  3. (megyesfalvi2023clinicalinsightsinto pages 1-2): Zsolt Megyesfalvi, Carl M. Gay, Helmut Popper, Robert Pirker, Gyula Ostoros, Simon Heeke, Christian Lang, Konrad Hoetzenecker, Anna Schwendenwein, Kristiina Boettiger, Paul A. Bunn, Ferenc Renyi‐Vamos, Karin Schelch, Helmut Prosch, Lauren A. Byers, Fred R. Hirsch, and Balazs Dome. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA: A Cancer Journal for Clinicians, 73:620-652, Jun 2023. URL: https://doi.org/10.3322/caac.21785, doi:10.3322/caac.21785. This article has 506 citations and is from a domain leading peer-reviewed journal.

  4. (huang2025molecularsubtypesand pages 1-2): Daoyuan Huang, Jingchao Wang, Li Chen, Weiwei Jiang, Hiroyuki Inuzuka, David K. Simon, and Wenyi Wei. Molecular subtypes and targeted therapeutic strategies in small cell lung cancer: advances, challenges, and future perspectives. Molecules, 30:1731, Apr 2025. URL: https://doi.org/10.3390/molecules30081731, doi:10.3390/molecules30081731. This article has 21 citations.

  5. (OpenTargets Search: small cell lung cancer): Open Targets Query (small cell lung cancer, 41 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  6. (megyesfalvi2023clinicalinsightsinto pages 5-5): Zsolt Megyesfalvi, Carl M. Gay, Helmut Popper, Robert Pirker, Gyula Ostoros, Simon Heeke, Christian Lang, Konrad Hoetzenecker, Anna Schwendenwein, Kristiina Boettiger, Paul A. Bunn, Ferenc Renyi‐Vamos, Karin Schelch, Helmut Prosch, Lauren A. Byers, Fred R. Hirsch, and Balazs Dome. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA: A Cancer Journal for Clinicians, 73:620-652, Jun 2023. URL: https://doi.org/10.3322/caac.21785, doi:10.3322/caac.21785. This article has 506 citations and is from a domain leading peer-reviewed journal.

  7. (huang2023incidencesurvivalcomparison pages 1-2): Liling Huang, Yu Feng, Tongji Xie, Haohua Zhu, Le Tang, and Yuankai Shi. Incidence, survival comparison, and novel prognostic evaluation approaches for stage iii-iv pulmonary large cell neuroendocrine carcinoma and small cell lung cancer. BMC Cancer, Apr 2023. URL: https://doi.org/10.1186/s12885-023-10797-3, doi:10.1186/s12885-023-10797-3. This article has 24 citations and is from a peer-reviewed journal.

  8. (uprety2025trendsinthe pages 1-2): Dipesh Uprety, Randell Seaton, Abesh Niroula, Tarik Hadid, Kaushal Parikh, and Julie J. Ruterbusch. Trends in the incidence and survival outcomes in patients with small cell lung cancer in the united states: an analysis of the seer database. Cancer Medicine, Feb 2025. URL: https://doi.org/10.1002/cam4.70608, doi:10.1002/cam4.70608. This article has 17 citations and is from a peer-reviewed journal.

  9. (uprety2025trendsinthe pages 2-4): Dipesh Uprety, Randell Seaton, Abesh Niroula, Tarik Hadid, Kaushal Parikh, and Julie J. Ruterbusch. Trends in the incidence and survival outcomes in patients with small cell lung cancer in the united states: an analysis of the seer database. Cancer Medicine, Feb 2025. URL: https://doi.org/10.1002/cam4.70608, doi:10.1002/cam4.70608. This article has 17 citations and is from a peer-reviewed journal.

  10. (megyesfalvi2023clinicalinsightsinto pages 27-27): Zsolt Megyesfalvi, Carl M. Gay, Helmut Popper, Robert Pirker, Gyula Ostoros, Simon Heeke, Christian Lang, Konrad Hoetzenecker, Anna Schwendenwein, Kristiina Boettiger, Paul A. Bunn, Ferenc Renyi‐Vamos, Karin Schelch, Helmut Prosch, Lauren A. Byers, Fred R. Hirsch, and Balazs Dome. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA: A Cancer Journal for Clinicians, 73:620-652, Jun 2023. URL: https://doi.org/10.3322/caac.21785, doi:10.3322/caac.21785. This article has 506 citations and is from a domain leading peer-reviewed journal.

  11. (redin2024smarca4controlsstate pages 1-2): Esther Redin, Harsha Sridhar, Yingqian A. Zhan, Barbara Pereira Mello, Hong Zhong, Vidushi Durani, Amin Sabet, Parvathy Manoj, Irina Linkov, Juan Qiu, Richard P. Koche, Elisa de Stanchina, Maider Astorkia, Doron Betel, Álvaro Quintanal-Villalonga, and Charles M. Rudin. Smarca4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and rest splicing. Journal of Hematology & Oncology, Jul 2024. URL: https://doi.org/10.1186/s13045-024-01572-3, doi:10.1186/s13045-024-01572-3. This article has 41 citations and is from a domain leading peer-reviewed journal.

  12. (huang2025molecularsubtypesand pages 7-9): Daoyuan Huang, Jingchao Wang, Li Chen, Weiwei Jiang, Hiroyuki Inuzuka, David K. Simon, and Wenyi Wei. Molecular subtypes and targeted therapeutic strategies in small cell lung cancer: advances, challenges, and future perspectives. Molecules, 30:1731, Apr 2025. URL: https://doi.org/10.3390/molecules30081731, doi:10.3390/molecules30081731. This article has 21 citations.

  13. (huang2025molecularsubtypesand pages 2-4): Daoyuan Huang, Jingchao Wang, Li Chen, Weiwei Jiang, Hiroyuki Inuzuka, David K. Simon, and Wenyi Wei. Molecular subtypes and targeted therapeutic strategies in small cell lung cancer: advances, challenges, and future perspectives. Molecules, 30:1731, Apr 2025. URL: https://doi.org/10.3390/molecules30081731, doi:10.3390/molecules30081731. This article has 21 citations.

  14. (patel2023smallcelllung pages 1-2): Shruti R. Patel and Millie Das. Small cell lung cancer: emerging targets and strategies for precision therapy. Cancers, 15:4016, Aug 2023. URL: https://doi.org/10.3390/cancers15164016, doi:10.3390/cancers15164016. This article has 39 citations.

  15. (redin2024smallcelllung pages 4-6): Esther Redin, Álvaro Quintanal-Villalonga, and Charles M. Rudin. Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity. Trends in Cancer, 10:935-946, Oct 2024. URL: https://doi.org/10.1016/j.trecan.2024.07.008, doi:10.1016/j.trecan.2024.07.008. This article has 47 citations and is from a peer-reviewed journal.

  16. (redin2024smallcelllung pages 11-13): Esther Redin, Álvaro Quintanal-Villalonga, and Charles M. Rudin. Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity. Trends in Cancer, 10:935-946, Oct 2024. URL: https://doi.org/10.1016/j.trecan.2024.07.008, doi:10.1016/j.trecan.2024.07.008. This article has 47 citations and is from a peer-reviewed journal.

  17. (redin2024smallcelllung pages 13-14): Esther Redin, Álvaro Quintanal-Villalonga, and Charles M. Rudin. Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity. Trends in Cancer, 10:935-946, Oct 2024. URL: https://doi.org/10.1016/j.trecan.2024.07.008, doi:10.1016/j.trecan.2024.07.008. This article has 47 citations and is from a peer-reviewed journal.

  18. (huang2025molecularsubtypesand pages 13-15): Daoyuan Huang, Jingchao Wang, Li Chen, Weiwei Jiang, Hiroyuki Inuzuka, David K. Simon, and Wenyi Wei. Molecular subtypes and targeted therapeutic strategies in small cell lung cancer: advances, challenges, and future perspectives. Molecules, 30:1731, Apr 2025. URL: https://doi.org/10.3390/molecules30081731, doi:10.3390/molecules30081731. This article has 21 citations.

  19. (megyesfalvi2023clinicalinsightsinto pages 6-7): Zsolt Megyesfalvi, Carl M. Gay, Helmut Popper, Robert Pirker, Gyula Ostoros, Simon Heeke, Christian Lang, Konrad Hoetzenecker, Anna Schwendenwein, Kristiina Boettiger, Paul A. Bunn, Ferenc Renyi‐Vamos, Karin Schelch, Helmut Prosch, Lauren A. Byers, Fred R. Hirsch, and Balazs Dome. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA: A Cancer Journal for Clinicians, 73:620-652, Jun 2023. URL: https://doi.org/10.3322/caac.21785, doi:10.3322/caac.21785. This article has 506 citations and is from a domain leading peer-reviewed journal.

  20. (chen2024advancesinpredictive pages 2-4): Tong Chen, Mingzhao Wang, Yanchao Chen, Yang Cao, and Yutao Liu. Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer. Cell & Bioscience, Sep 2024. URL: https://doi.org/10.1186/s13578-024-01283-9, doi:10.1186/s13578-024-01283-9. This article has 24 citations and is from a peer-reviewed journal.

  21. (papavassiliou2024p53andrb pages 4-5): Kostas A. Papavassiliou, Amalia A. Sofianidi, Vassiliki A. Gogou, Nektarios Anagnostopoulos, and Athanasios G. Papavassiliou. P53 and rb aberrations in small cell lung cancer (sclc): from molecular mechanisms to therapeutic modulation. International Journal of Molecular Sciences, 25:2479, Feb 2024. URL: https://doi.org/10.3390/ijms25052479, doi:10.3390/ijms25052479. This article has 39 citations.

  22. (zugazagoitia2024factsandhopes pages 2-3): Jon Zugazagoitia, Handerson Osma, Javier Baena, Alvaro C. Ucero, and Luis Paz-Ares. Facts and hopes on cancer immunotherapy for small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 30:2872-2883, Apr 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-1159, doi:10.1158/1078-0432.ccr-23-1159. This article has 29 citations.

  23. (megyesfalvi2023clinicalinsightsinto pages 10-11): Zsolt Megyesfalvi, Carl M. Gay, Helmut Popper, Robert Pirker, Gyula Ostoros, Simon Heeke, Christian Lang, Konrad Hoetzenecker, Anna Schwendenwein, Kristiina Boettiger, Paul A. Bunn, Ferenc Renyi‐Vamos, Karin Schelch, Helmut Prosch, Lauren A. Byers, Fred R. Hirsch, and Balazs Dome. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA: A Cancer Journal for Clinicians, 73:620-652, Jun 2023. URL: https://doi.org/10.3322/caac.21785, doi:10.3322/caac.21785. This article has 506 citations and is from a domain leading peer-reviewed journal.

  24. (chen2024aretrospectivestudy pages 1-2): Yao Chen, Ling Yao, Qingquan Chen, Yiming Hu, Xi Zhu, Rongrong Dai, Xiaoyang Chen, Yifu Zeng, Yong Zhu, Duanhong Song, and Yixiang Zhang. A retrospective study on the impact of radiotherapy on the survival outcomes of small cell lung cancer patients based on the seer database. Scientific Reports, Jul 2024. URL: https://doi.org/10.1038/s41598-024-65314-8, doi:10.1038/s41598-024-65314-8. This article has 8 citations and is from a peer-reviewed journal.

  25. (cheng2024benmelstobartanlotiniband pages 1-2): Ying Cheng, Jianhua Chen, Wei Zhang, Chao Xie, Qun Hu, Ningning Zhou, Chun Huang, Shihong Wei, Hong Sun, Xingya Li, Yan Yu, Jinhuo Lai, Huaping Yang, Haohui Fang, Hualin Chen, Peng Zhang, Kangsheng Gu, Qiming Wang, Jianhua Shi, Tienan Yi, Xingxiang Xu, Xianwei Ye, Daqing Wang, Conghua Xie, Chunling Liu, Yulong Zheng, Daren Lin, Wu Zhuang, Ping Lu, Guohua Yu, Jinzhang Li, Yuhai Gu, Baolan Li, Rong Wu, Ou Jiang, Zaiyi Wang, Guowu Wu, Haifeng Lin, Diansheng Zhong, Yanhua Xu, Yongqian Shu, Di Wu, Xingwu Chen, Jie Wang, Minghui Wang, and Runxiang Yang. Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial. Nature Medicine, 30:2967-2976, Jul 2024. URL: https://doi.org/10.1038/s41591-024-03132-1, doi:10.1038/s41591-024-03132-1. This article has 154 citations and is from a highest quality peer-reviewed journal.

  26. (megyesfalvi2023clinicalinsightsinto pages 9-9): Zsolt Megyesfalvi, Carl M. Gay, Helmut Popper, Robert Pirker, Gyula Ostoros, Simon Heeke, Christian Lang, Konrad Hoetzenecker, Anna Schwendenwein, Kristiina Boettiger, Paul A. Bunn, Ferenc Renyi‐Vamos, Karin Schelch, Helmut Prosch, Lauren A. Byers, Fred R. Hirsch, and Balazs Dome. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA: A Cancer Journal for Clinicians, 73:620-652, Jun 2023. URL: https://doi.org/10.3322/caac.21785, doi:10.3322/caac.21785. This article has 506 citations and is from a domain leading peer-reviewed journal.

  27. (megyesfalvi2023clinicalinsightsinto pages 10-10): Zsolt Megyesfalvi, Carl M. Gay, Helmut Popper, Robert Pirker, Gyula Ostoros, Simon Heeke, Christian Lang, Konrad Hoetzenecker, Anna Schwendenwein, Kristiina Boettiger, Paul A. Bunn, Ferenc Renyi‐Vamos, Karin Schelch, Helmut Prosch, Lauren A. Byers, Fred R. Hirsch, and Balazs Dome. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA: A Cancer Journal for Clinicians, 73:620-652, Jun 2023. URL: https://doi.org/10.3322/caac.21785, doi:10.3322/caac.21785. This article has 506 citations and is from a domain leading peer-reviewed journal.

  28. (bonanno2024realworldimpactof pages 1-2): Laura Bonanno, Lorenzo Calvetti, Alessandro Dal Maso, Alberto Pavan, Loc Carlo Bao, Mattia De Nuzzo, Stefano Frega, Giulia Sartori, Alessandra Ferro, Giulia Pasello, Paolo Morandi, Giuseppe Aprile, and Valentina Guarneri. Real-world impact of the introduction of chemo-immunotherapy in extended small cell lung cancer: a multicentric analysis. Frontiers in Immunology, Jan 2024. URL: https://doi.org/10.3389/fimmu.2024.1353889, doi:10.3389/fimmu.2024.1353889. This article has 11 citations and is from a peer-reviewed journal.

  29. (zugazagoitia2024factsandhopes pages 3-3): Jon Zugazagoitia, Handerson Osma, Javier Baena, Alvaro C. Ucero, and Luis Paz-Ares. Facts and hopes on cancer immunotherapy for small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 30:2872-2883, Apr 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-1159, doi:10.1158/1078-0432.ccr-23-1159. This article has 29 citations.

  30. (megyesfalvi2023clinicalinsightsinto pages 19-20): Zsolt Megyesfalvi, Carl M. Gay, Helmut Popper, Robert Pirker, Gyula Ostoros, Simon Heeke, Christian Lang, Konrad Hoetzenecker, Anna Schwendenwein, Kristiina Boettiger, Paul A. Bunn, Ferenc Renyi‐Vamos, Karin Schelch, Helmut Prosch, Lauren A. Byers, Fred R. Hirsch, and Balazs Dome. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA: A Cancer Journal for Clinicians, 73:620-652, Jun 2023. URL: https://doi.org/10.3322/caac.21785, doi:10.3322/caac.21785. This article has 506 citations and is from a domain leading peer-reviewed journal.

  31. (zugazagoitia2024factsandhopes pages 7-8): Jon Zugazagoitia, Handerson Osma, Javier Baena, Alvaro C. Ucero, and Luis Paz-Ares. Facts and hopes on cancer immunotherapy for small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 30:2872-2883, Apr 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-1159, doi:10.1158/1078-0432.ccr-23-1159. This article has 29 citations.

  32. (bonanno2024realworldimpactof pages 3-5): Laura Bonanno, Lorenzo Calvetti, Alessandro Dal Maso, Alberto Pavan, Loc Carlo Bao, Mattia De Nuzzo, Stefano Frega, Giulia Sartori, Alessandra Ferro, Giulia Pasello, Paolo Morandi, Giuseppe Aprile, and Valentina Guarneri. Real-world impact of the introduction of chemo-immunotherapy in extended small cell lung cancer: a multicentric analysis. Frontiers in Immunology, Jan 2024. URL: https://doi.org/10.3389/fimmu.2024.1353889, doi:10.3389/fimmu.2024.1353889. This article has 11 citations and is from a peer-reviewed journal.

  33. (zugazagoitia2024factsandhopes pages 5-6): Jon Zugazagoitia, Handerson Osma, Javier Baena, Alvaro C. Ucero, and Luis Paz-Ares. Facts and hopes on cancer immunotherapy for small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 30:2872-2883, Apr 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-1159, doi:10.1158/1078-0432.ccr-23-1159. This article has 29 citations.

  34. (patel2023smallcelllung pages 6-8): Shruti R. Patel and Millie Das. Small cell lung cancer: emerging targets and strategies for precision therapy. Cancers, 15:4016, Aug 2023. URL: https://doi.org/10.3390/cancers15164016, doi:10.3390/cancers15164016. This article has 39 citations.

  35. (sen2024emergingadvancesin pages 1-3): Triparna Sen, Nobuyuki Takahashi, Subhamoy Chakraborty, Naoko Takebe, Amin H. Nassar, Nagla A. Karim, Sonam Puri, and Abdul Rafeh Naqash. Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer. Nature reviews. Clinical oncology, 21:610-627, Jul 2024. URL: https://doi.org/10.1038/s41571-024-00914-x, doi:10.1038/s41571-024-00914-x. This article has 137 citations.

  36. (eglenenpolat2024atelomeretargetingdrug pages 1-2): Buse Eglenen-Polat, Ryan R. Kowash, Hai-Cheng Huang, Silvia Siteni, Mingrui Zhu, Kenian Chen, Matthew E. Bender, Ilgen Mender, Victor Stastny, Benjamin J. Drapkin, Prithvi Raj, John D. Minna, Lin Xu, Jerry W. Shay, and Esra A. Akbay. A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer. Nature Communications, Jan 2024. URL: https://doi.org/10.1038/s41467-024-44861-8, doi:10.1038/s41467-024-44861-8. This article has 27 citations and is from a highest quality peer-reviewed journal.

Artifacts